NEW YORK An international team of researchers has used transcriptomic data from ulcerative colitispatients to develop a predicted polygenic transcriptional risk score, or PPTRS,that can identify UC-affected individuals at fivefold elevated risk of progressing to surgical resection of the large bowel.

In a paper published on Thursday in the American Journal of Human Genetics, the Georgia Institute of Technology-led team noted that 5 percent to 10 percent of people with UC require bowel resection, or colectomy, within five years of diagnosis, but that polygenic risk scores based on genome-wide association studies generally don't provide meaningful prediction of progression to surgery. However, studies of Crohn's disease have shown that gene expression profiling of GWAS-significant genes provides some stratification of risk of progression to complicated disease through transcriptional risk scoring, or TRS.

In their paper, the researchers demonstrated that a measured TRS based on bulk rectal gene expression in a cohort of UC patients had a positive predictive value approaching 50 percent for colectomy. Single-cell profiling demonstrated that the disease-associated genes were active in multiple diverse cell types from both the epithelial and immune compartments, and expression quantitative trait locusanalysis identified genes with differential effects at baseline and the one-year follow-up, the researchers said. But for the most part, they found that differential expression associated with colectomy risk was independent of local genetic regulation.

Overall, their data suggested that prediction of gene expression from relatively small transcriptome datasets can be used in conjunction with transcriptome-wide association studies for stratification of risk of disease complications.

The researchers began by performing differential expression analysis between baseline rectal RNA-seq biopsies of individuals in the PROTECT multicenter pediatric inception cohort study of response to standardized colitis therapy. Analyses were done on 21 affected individuals who progressed to colectomy and 310 who did not. They identified downregulation of 783 transcripts in the individuals who underwent colectomy and upregulation of 1,405 transcripts overall.

They also obtained rectal biopsy RNA-seq data for 92 affected individuals at week 52 and observed a marked shift in gene expression at follow-up, prompting them to ask whether local regulation of the gene expression might contribute to this effect. They found that there were 72 SNPs that were significantly regulating 308 genes at both time points.

Further examination of the expression of colectomy-associated genes in a single-cell RNA-seq dataset obtained from rectal biopsies provided strong evidence that both epithelial and immune cells contributed to the risk of disease progression, the researchers said.

The researchers then performed a TWAS to capture the effects of all polymorphisms within 1 Mb of each transcript expressed in the PROTECT rectal biopsies and then used the weights to predict gene expression in a validation cohort from the UK Biobank. They tested for differential predicted gene expression in 70 percent of the validation samples and discovered about 800 genes either upregulated or downregulated in UC-affected individuals relative to non-IBD control individuals. They then derived a PPTRS for UC based on the effect sizes of the minor alleles and applied it to the remaining 30 percent of the validation samples, as well as to the PROTECT genotypes, and found that the PPTRS efficiently discriminated UC-affected individuals from non-IBD control individuals.

Significantly, it also discriminated the individuals who underwent colectomy versus those who didn't in both the UK Biobank and PROTECT.

"More extensive single-cell profiling, combined with cell-type-specific genetic analysis of gene expression, is likely to lead to the development of even better transcriptional risk signatures," the authors concluded. "It is also likely that such focused and personalized analysis may highlight specific pathological mechanisms active in particular affected individuals."

They did note, however, that these results were limited by the relatively small sample size of colectomies in the PROTECT study, and that validation of cross-ancestry assessments and the evaluation of the consistency of gene expression prediction across populations should be a high priority.

In an email, corresponding author and GIT researcher Greg Gibson noted that while the study's multiple layers of replication show that transcriptional profiling of the rectum greatly enhances risk stratification for risk of colectomy, this was not a clinical trial, so the approach is not yet approved for evaluation of patients.

"We hope that it will progress to implementation in the near future," he added."The prediction from genotypes alone is less likely to have clinical utility since the precision is still quite low, so that aspect is more research oriented."

He further noted that the approach he and his colleagues used could also be applied to a wide range of diseases, and that they are pursuing that research.

Follow this link:
Ulcerative Colitis Study Analyzes Gene Expression to Measure Risk of Progression to Surgery - GenomeWeb

Recommendation and review posted by Bethany Smith

Brain development that occurs after birth is also important. Rebecca Saxe at MIT is working to understand the brain structures and activities responsible for social cognition, which allows us to consider the mental states of other people.

Saxe has discovered a particular brain region that is key; by studying how activity in this region and others changes over the course of childhood, she may be able to understand how social abilities develop. She has also found that these brain activity patterns are altered in people with autism spectrum disorders.

Even though researchers are starting to understand some of the processes that govern development and have identified things that can derail it, were far from being able to intervene when such problems occur. But as we gain insights, we could someday test therapies or other ways to address these developmental issues.

Computational neuroscientists use mathematical models to better understand how networks of brain cells help us interpret what we see and hear, integrate new information, create and store memories, and make decisions.

Understanding how the activity of neurons governs cognition and behavior could lead to ways to improve memory or understand disease processes.

Terry Sejnowski, a computational neurobiologist at the Salk Institute, has built a computer model of the prefrontal cortex and analyzed its performance on a task in which a person (or machine) has to sort cards according to a rule thats always changing. While humans are great at adapting, machines generally struggle. But Sejnowskis computer, which imitates information flow patterns observed in the brain, performed well on this task. This research could help machines think more like humans and adapt more quickly to new conditions.

Aude Oliva, the MIT director of the MIT-IBM Watson AI Lab, uses computational tools to model and predict how brains perceive and remember visual information. Her research shows that different images result in certain patterns of activity both in the monkey cortex and in neural network models, and that these patterns predict how memorable a certain image will be.

Research like Sejnowskis may inspire smarter machines, but it could also help us understand disorders in which the function of the prefrontal cortex is altered, including schizophrenia, dementia, and the effects of head trauma.

Researchers are trying to determine the genetic and environmental risk factors for neurodegenerative diseases, as well as the diseases underlying mechanisms.

NHUNG LE

Improving prevention, early detection, and treatment for diseases like Alzheimers, Parkinsons, Huntingtons, chronic traumatic encephalopathy, and ALS would benefit millions of people around the world.

Yakeel Quiroz, at Massachusetts General Hospital, studies changes in brain structure and function that occur before the onset of Alzheimers symptoms. Shes looking for biomarkers that could be used for early detection of the disease and trying to pinpoint potential targets for therapeutics. One potential biomarker of early-onset Alzheimers that shes founda protein called NfLis elevated in the blood more than two decades before symptoms appear. Quiroz has also identified a woman with a protective genetic mutation that kept her from developing cognitive impairments and brain degeneration even though her brain showed high levels of amyloid, a protein implicated in Alzheimers development. Studying the effects of this beneficial mutation could lead to new therapies.

Researchers at the Early Detection of Neurodegenerative Diseases initiative in the United Kingdom are analyzing whether digital data collected by smartphones or wearables could give early warnings of disease before symptoms develop. One of the initiatives projectsa partnership with Boston Universitywill collect data using apps, activity tracking, and sleep tracking in people with and without dementia to identify possible digital signatures of disease.

As we learn more about the underlying causes of neurodegenerative diseases, researchers are trying to translate this knowledge into effective treatments. Advanced clinical trials targeting newly understood mechanisms of disease are currently under way for many neurodegenerative disorders, including Alzheimers, Parkinsons, and ALS.

Connectomics researchers map and analyze neuronal connections, creating a wiring diagram for the brain.

Understanding these connections will shed light on how the brain functions; many projects are exploring how macro-scale connections are altered during development, aging, or disease.

Mapping these connections isnt easythere may be as many as 100 trillion connections in the human brain, and theyre all tiny. Researchers need to find the best ways to label specific neurons and track the connections they make to other neurons in remote parts of the brain, refine the technology to collect these images, and figure out how to analyze the mountains of data that this process produces.

See the original post here:
Eight ways scientists are unwrapping the mysteries of the human brain - MIT Technology Review

Recommendation and review posted by Bethany Smith

State College, Pennsylvania., August 30, 2021 / PRNewswire / -NeuExcell Therapeutics (www.neuexcell.com), A gene therapy company focused on neurodegenerative diseases has announced a Series Pre-A funding round of over $ 10 million. The round was led by Co-Win Ventures and was attended by other institutional investors Yuan Bio, Oriza Seed, Tsingyuan and Inno Angel.

We are honored to join this very reputable group of investors, he said. Peter Tombros, Chairman of the Board of Directors of NeuExcell Therapeutics. Investor experience and support will enable us to leverage our unique neuroregenerative gene therapy platform across multiple neurodegenerative indications. This funding strength validates our strategy and biotechnology. Further examine our science in the industry.

Professor Gong Chen, co-founder and chief scientific advisor of the company, said: There is an urgent need for breakthrough therapies like us.

I think this is a great opportunity to invest in experienced leadership, he said. Xin Huang, Managing Partner of Co-Win Ventures. NeuExcells unique technology has the potential to act as a platform for treating many neurodegenerative diseases, providing hope for breakthrough new therapies for patients who do not have the right choices today.

With the end of this successful pre-A round, we welcome him. Xin Huang Jonathan Sun attended the board meeting.

About NeuExcellTherapeutics

NeuExcell is a privately held early stage genetic engineering company headquartered in Pennsylvania, USA When Shanghai, China.. Its mission is to improve the lives of patients suffering from neurodegenerative diseases and damage to the central nervous system. Based on Professor Gong Chens scientific research, we have developed a potentially destructive nerve repair technique through the conversion of astrocytes to neurons. In vivo By introducing neural transcription factors through adeno-associated virus (AAV) -based gene therapy. NeuExcells pipeline covers major neurodegenerative diseases such as stroke, Huntingtons disease, amyotrophic lateral sclerosis (ALS), Alzheimers disease, Parkinsons disease, traumatic brain injury, spinal cord injury, and glioma. increase.

About Co-Wof Venture

Founded in 2009, Co-Win Ventures is an early stage investor in healthcare and TMT with a focus on equality, transparency, sharing and innovation. Co-Wins business network China When USA..Total AUM is about US $ 1 billion, Co-Win aims to be a reliable partner for great entrepreneurs to build breakthrough technologies and businesses. Co-Win Ventures has helped more than 140 portfolio companies, including leading leaders in their respective sub-sectors, including Cytek, Connect, Thrive (acquired by Nasdaq-listed company EXAS), Taimei Technology, Genecast, Sinovation and Augta. ..

To download multimedia, view the original content.https://www.prnewswire.com/news-releases/neuexcell-therapeutics-raises-10-million-series-pre-a-round-to-continue-its-company-growth-301364144.html

Source NeuExcellTherapeutics

NeuExcell Therapeutics Raises Over $ 10 Million Series Before Round To Keep The Company Growing | Around The Web-Pennsylvania

Source link NeuExcell Therapeutics Raises Over $ 10 Million Series Before Round To Keep The Company Growing | Around The Web-Pennsylvania

Continued here:
NeuExcell Therapeutics Raises Over $ 10 Million Series Before Round To Keep The Company Growing | Around The Web-Pennsylvania - Pennsylvania News...

Recommendation and review posted by Bethany Smith

SAN FRANCISCO--(BUSINESS WIRE)--AllStripes (Company), a healthcare technology company dedicated to unlocking treatments for people affected by rare diseases, today announced the Company completed a $50 million Series B financing round.

The financing was led by Lux Capital, a current investor, joined by JAZZ Venture Partners, Spark Capital, Medidata Solutions (a Dassault Systmes company), McKesson Ventures, and Maveron, along with angel investors including Arif Nathoo, CEO of Komodo Health, and Leila Zegna, Director of the Kabuki Syndrome Foundation.

The funding will support launching 100 new rare disease research programs while expanding global operational footprint, technology and data automation enhancements to improve research insights, further developing the platform capabilities to enhance the user experience and strengthen the life sciences offerings, and continuing to invest in growing the companys team to support creating the playbook for rare disease research.

Beginning research on a rare condition can feel like being dropped into a new world without a map and we are on a mission to change that with data, said Nancy Yu, CEO and Co-founder, AllStripes. Were proud that so many of our current investors have recognized the progress weve made and are continuing to support our vision to transform rare disease research. This investment will allow us to better support the rare disease community, where each persons experience is essential to understanding disease progression - ultimately leading to new treatments for rare disease patients around the globe.

AllStripes has a successful track record of bringing together patient organizations, families, experts and life science partners to advance research, said Adam Goulburn, Partner, Lux Capital and AllStripes board member. If we are going to improve rare disease treatments, these groups must work together. We believe in AllStripes vision to transform rare disease research and empower patients. If the past year showed us anything, it is that patients want a voice when it comes to their health, and their engagement with research is invaluable.

There are more than 7,000 rare diseases and only 5 percent have treatments. By working with AllStripes, we hope to improve the number of treatments available by accelerating research for rare diseases, said James M. Wilson, M.D., Ph.D., Rose H. Weiss Professor and Director, Orphan Disease Center; Director, Gene Therapy Program at the University of Pennsylvania; Professor in Departments of Medicine and Pediatrics, Perelman School of Medicine.

AllStripes is currently partnering with more than 30 patient advocacy organizations across its 40 conditions, supporting more than 3,000 users to date. As a public benefit corporation (PBC), AllStripes is advocating for the importance of real-world evidence in development of treatments and is continuing to build tools that make research more inclusive for the global rare disease community. The Company is committed to transparent data collection and sharing data across the life sciences continuum to advance clinical research.

AllStripes collaborates with various biopharmaceutical companies and other entities on real-world evidence studies, including: HemoShear Therapeutics, Inc., Orphan Disease Center at the University of Pennsylvania, Taysha Gene Therapies, Inc., UCB Biopharma SRL, and Novartis Pharma AG. These joint research programs aim to enhance clinical understanding of rare disease treatment research. AllStripes and the University of Pennsylvania's Orphan Disease Center are focused on clinical understanding of Lesch-Nyhan disease and Crigler Najjar syndrome type 1, with the goal of facilitating therapeutic discovery for both conditions. One of AllStripes most recent partnerships with HemoShear Therapeutics aims to gather real-world evidence on patients' medical experience with serious metabolic diseases through the Journey to Understand MMA and PA (JUMP) study.

To learn more about AllStripes, its partners and its commitment to the rare disease community, please visit allstripes.com.

About AllStripesAllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes has developed a technology platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that empowers patients and families to securely participate in treatment research online and benefit from their own medical data. AllStripes was founded by CEO Nancy Yu and technology developer Onno Faber, following his diagnosis and journey with the rare disease neurofibromatosis type 2. The company is backed by Lux Capital, JAZZ Venture Partners, Spark Capital, Medidata Solutions, McKesson Ventures, Maveron, and a number of angel investors. For more information, visit http://www.allstripes.com.

About Lux CapitalLux Capital invests in emerging science and technology ventures at the outermost edges of what is possible. We partner with iconoclastic inventors challenging the status quo and the laws of nature to bring their futuristic ideas to life. Over the past two decades, Lux has expanded from its New York City roots to Silicon Valley, and built a $4 billion AUM firm of more than 30 full-time professionals, with the versatility to invest at any stage.

JAZZ Venture PartnersJAZZ Venture Partners invests in companies that extend the boundaries of human performance improving how we live, learn, work, play, and experience the world. JAZZ seeks breakthroughs at the frontiers of technology and science, such as advances in artificial intelligence, neurobiology, augmented reality, and closed-loop human-computer systems. JAZZ portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise. More information about JAZZ can be found at http://www.jazzvp.com.

Read the rest here:
AllStripes Announces $50 Million Series B Financing to Advance Global Rare Disease Research - Business Wire

Recommendation and review posted by Bethany Smith

VANCOUVER, British Columbia & BASEL, Switzerland--(BUSINESS WIRE)--Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, today announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited (Takeda) for the development and commercialization of novel nonviral gene therapies to treat up to two undisclosed rare liver diseases. This is the second collaboration between Genevant and Takeda, following an earlier 2021 agreement to develop nucleic acid therapeutics directed to specified targets in hepatic stellate cells to treat liver fibrosis.

LNP provides a compelling approach to deliver on the promise of gene therapy, and our leadership position in the LNP space is well established. We have enjoyed working with our Takeda colleagues to develop hepatic stellate cell-directed treatments to treat liver fibrosis and are delighted to expand the relationship further with this second collaboration, said Pete Lutwyche, Ph.D., president and chief executive officer, Genevant Sciences Corporation.

Building on our existing foundation with Genevant in liver fibrosis, were excited to expand our work together to develop life-altering, nonviral gene therapies for specified rare liver diseases, said Bernard Allan, head of liver disease research at Takeda. Genevants expertise in the development of LNPs for clinical applications, coupled with Takedas drug development capabilities and history in gastroenterology, gives us a great opportunity to develop new treatment options for patients with liver disorders.

Under the terms of the agreement, Genevant is eligible to receive up to $303 million in upfront and potential milestone payments, plus royalties on future product sales. Takeda has exclusive rights to utilize Genevants LNP technology in the development and commercialization of specified nonviral gene therapies for up to two undisclosed rare liver diseases.

About Genevant Sciences

Genevant Sciences is a leading nucleic acid delivery company with world-class platforms, the industrys most robust and expansive lipid nanoparticle (LNP) patent estate, and decades of experience and expertise in nucleic acid drug delivery and development. The Companys scientists have pioneered LNP delivery of nucleic acids for over 20 years, and the Companys LNP platform, which has been studied across more than a dozen discrete product candidates and is the delivery technology behind the first and only approved RNAi-LNP (patisiran), enables a wide array of RNA-based applications, including vaccines, therapeutic protein production, and gene editing. For more information, please visit http://www.genevant.com.

Go here to read the rest:
Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nonviral Gene Therapies for Up to Two Rare Liver...

Recommendation and review posted by Bethany Smith

Using cells from brain tumour patients as a 3D printing material, researchers have made a model of their tumour to test the efficacy of potential treatments before using them for real inside the body. "A chunk" of the tumour from a glioblastoma patient is used to print a model matching their MRI scans. The patient's blood is then pumped through the printed tumour, made with a compound that mimics the brain, followed by a drug or therapeutic treatment. While previous research has used such "bioprinting" to simulate cancer environments, the Tel Aviv University scientists involved in this research say they are the first to print a "viable" tumour.

Medulloblastoma, whilst being a common paediatric malignant central nervous system tumour, represent a small proportion of brain tumours in adults. This research reports on theunique subgroup-specific cytogenetic features of adult medulloblastoma, which are distinct from those in younger patients, and correlate with survival disparities. The findings suggest that clinical trials that incorporate new strategies tailored to high-risk adult medulloblastoma patients are urgently needed. These findings complement theimportant progress being made on medulloblastoma by researchers at our Research Centre at QMUL.

Chronobiology is a promising area for research in our area as circadian clock genes are linked to tumour biology and outcomes in multiple cancers, including glioma. In this research, the relationship between circadian clock genes, IDH mutational status, and prognosis in glioma patients was examined to try and gain further understanding into theassociation between circadian clock gene expression, the glioma microenvironment and patient survival.

Researchers in Brazil have discovered a set of biomarkers that can be used to predict which patients diagnosed with glioblastoma may have tumours that are more resistant to radiation therapy. This discovery could help doctors choose the treatment that should enable patients to live longer. Glioblastoma usually has to be surgically removed, followed by chemotherapy or radiation therapy, or both, to eliminate what could not be surgically removed and ensure the tumour does not return. However, patient survival tends to be low owing to the tumours resistance to treatment. According to most estimates, 80% of patients submitted to radiation therapy suffer a relapse a few months later. These researchers claim that their study provides important information for use in screening patients prior to deciding whether radiation therapy should be used. Its a large signature. We identified 31 genes that may indicate resistance or sensitivity to radiation when altered. So, its possible to verify whether there are tumour cells that are highly resistant to radiation, potentially assisting physicians in deciding on the optimal treatment.

Some facts and figures from the American Cancer Society in a new report illustrating thatalthough incidence rates of adult brain tumours are decreasing 5-year survival rates remain low.

There are over 120 different types of brain tumours and although distinguishing between them can be difficult it is nevertheless essential for effective treatment. This year, the Gertrud Reemtsma Foundation isawarding the International Prize for Translational Neuroscience to two researchers who have made a significant contribution to improving the diagnosis of brain tumours. Hai Yan from Duke University School of Medicine was instrumental in identifying two tumour proteins that are typical for certain sub-groups of gliomas. Andreas von Deimling and his group from the University of Heidelberg have developed antibodies that bind to these altered proteins. The tumours can now be classified at the molecular level. A patients cancer can thus be classified more precisely and the therapy adapted accordingly.

There wont be a research update next week but it will return on 10th September.

Related Reading:

If you found this story interesting or helpful,sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

View post:
3D printed tumours, adult medulloblastoma and the circadian clock - Brain Tumour Research

Recommendation and review posted by Bethany Smith

The latest Cell and Gene Therapy Market report serves as a valuable resource for data concerning the industrys trajectory over the forecast duration. It critically examines the key growth stimulants, bottlenecks, and rewarding prospects that are influencing the industry dynamics. Moreover, the literature consists of detailed segmentation data, as well as in-depth profiles of key companies in this domain.

Experts analysts state that Cell and Gene Therapy market size is anticipated to amass notable gains, accumulating a valuation of XX USD over the projected timeframe 2021-2026. In addition, projections for the various sub-markets are also validated in the report. Proceeding further, the research literature is well equipped with different methodologies to assist the stakeholders in seamlessly navigating any form of business crisis.

Key highlights from the Cell and Gene Therapy market report:

Request Sample Copy of this Report @ https://www.nwdiamondnotes.com/request-sample/3811

Cell and Gene Therapy market segments covered in the report:

Product gamut: Rare Diseases , Oncology , Hematology , Cardiovascular , Ophthalmology , Neurology and Other Therapeutic Classes

Application spectrum: Pharmaceutical and Biotechnology Companies , Research and Academic Institutions , Contract Research Organizations (CROs) , Hospital and Others

Competitive dashboard:

Regional bifurcation:

Key Questions Addressed by the Report

What Are the Key Opportunities in Global Cell and Gene Therapy Market?

What Will Be the Growth Rate from 2021 to 2026?

What Are the Factors That Will Impact/Drive the Market?

Which Segment/Region Will Have Highest Growth?

What is the Role of Key Players in the Value Chain?

What is the Competitive Landscape in the Industry?

Request Customization on This Report @ https://www.nwdiamondnotes.com/request-for-customization/3811

Follow this link:
Cell and Gene Therapy Market Forecasts to 2026: Global Industry Growth, Share, Size, Trends and Segmentation Report - Northwest Diamond Notes

Recommendation and review posted by Bethany Smith

The latest published report namely Cancer Gene Therapy Market Growth 2021-2028 added by DBMR offers an insightful take on the historical data of the market and predictions for 2021 to 2028 time-period. The report provides an understanding of the Cancer Gene Therapy industry competitors, the sales channel, growth potential, potentially disruptive trends, industry product innovations and the value/volume of size, market segments, and market share of the best actors/products. Current market trends and dynamics are assessed which helps in mapping the track of the global market. A chapter-wise format has been used to ease the readability and complexity of the data. Each chapter is further categorized into its respective segments containing well-structured data.

According to DBMR, the GlobalCancer Gene Therapy Marketis expected to see a growth rate of 32.54%. The high success rate of cancer gene therapy along with clinical trial and the preclinical trial is gaining popularity among the patient which is leading towards the market.

Download Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on this Industry@https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cancer-gene-therapy-market

Market Overview of Global Cancer Gene Therapy

Increase in funding of research and development in the activities of cancer gene therapy along with rise in prevalence of cancer is likely to accelerate the growth of the cancer gene therapy market in the forecast period of 2020-2027. On the other hand, the favourable government regulations for therapy is further going to boost various opportunities that will lead to the growth of the cancer gene therapy market in the above mentioned forecast period. High cost involved in gene therapy along with unwanted immune responses wills likely to hamper the growth of the cancer gene therapy market in the above mentioned forecast period.

The topic of market segmentation covers research and analysis based on application, vertical, deployment model, end user, and geography. In addition, competitive analysis assists to get ideas about the strategies of key players in the market via an international Cancer Gene Therapy report. Some of these strategies can be named as; new product launches, expansions, agreements, partnerships, joint ventures, acquisitions, and others that help to broaden their footprints in the Cancer Gene Therapy industry. The market share of key competitors on global level is studied where main regions such as Europe, North America, Asia Pacific and South America are covered in the reliable Cancer Gene Therapy market report.

To Get the Short-Term and Long-Term Impact of COVID-19 on this Market@https://www.databridgemarketresearch.com/request-covid-19/global-cancer-gene-therapy-market

The titled segments and sub-section of the market are illuminated below

By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer)

By End User (Hospitals, Oncology Institutes, Biotechnological Companies, Clinical Research Laboratories)

Top Key Manufactures or Players (this may not be a complete list and extra companies can be added upon request):

Adaptimmune

GlaxoSmithKline plc

bluebird bio, Inc

Merck & Co., Inc

CELGENE CORPORATION

Anchiano Therapeutics

Achieve Life Sciences

..

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart)@https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-gene-therapy-market

Global Cancer Gene Therapy Market Scope and Market Size

Cancer gene therapy market is segmented on the basis of therapy and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on therapy, the cancer gene therapy market is segmented into oncolytic virotherapy, gene induced immunotherapy and gene transfer. The oncolytic virotherapy is further sub-segmented into adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus and others. The gene induced immunotherapy is further sub-segmented into delivery of cytokines gene and delivery of tumor antigen gene. The gene transfer is further sub-segmented into naked/plasmid vectors, electroporation, sonoporation, magnetofection and gene gun.

Cancer gene therapy market has also been segmented based on the end user into hospitals, oncology institutes, biotechnological companies and clinical research laboratories.

According to the Regional Segmentation the Cancer Gene Therapy Market provides the Information covers following regions:

North America

South America

Asia & Pacific

Europe

MEA (Middle East and Africa)

The key countries in each region are taken into consideration as well, such as United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

North America dominates the cancer gene therapy market due to the advanced healthcare infrastructure along with rise in R & D expenditure, while Asia-Pacific is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 due to the improving healthcare infrastructure and government initiatives.

For More Information or Query or Customization Before Buying, Visit@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-gene-therapy-market

Scope of Report:

The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. This report will help you to establish a landscape of industrial development and characteristics of the Cancer Gene Therapy market. The Global Cancer Gene Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, price, cost, revenue and gross margins.

Important Features that are under offering & key highlights of the report:

Market Data Segmentation with production, consumption, revenue (million USD), and Price Analysis

Detailed overview of Cancer Gene Therapy market

Changing market dynamics of the industry and Impact of Influencing Factors

In-depth market segmentation by Type, Application and other major segments etc.

To analyse and forecast the Global Cancer Gene Therapy market, in terms of value and volume.

Which segment has the potential to gain the highest market share?

To help decision maker from new offer perspective and benchmark existing marketing strategy.

Correlate cost structure historical data with key business segments.

Analyse marketing contribution and customer acquisition by up-selling and cross selling.

Identifying Influencing factors keeping Global Cancer Gene Therapy Market Intense, factored with periodic analysis of CR4 & CR8 concentration ratio & HHI Index.

Order a Copy of Cancer Gene Therapy Market Report@https://www.databridgemarketresearch.com/checkout/buy/singleuser/global-cancer-gene-therapy-market

With tables and figures helping analyze worldwide Global Cancer Gene Therapy market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Major Highlights of TOC:

Chapter One: Market Overview

1.1. Introduction

1.2. Scope/Objective of the Study

Chapter Two: Executive Summary

2.1. Introduction

Chapter Three: Market Dynamics

3.1. Introduction

3.2. Market Drivers, Trends, Challenges, Opportunities

Chapter Four: Market Factor Analysis

4.1. Porters Five Forces

4.2. Supply/Value Chain

4.3. PESTEL analysis

4.4. Market Entropy

4.5. Impact Analysis Post COVID-19

Continued !!!

Chapter Nine: Methodology and Data Source

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Our Other Reports:

Remote Patient Monitoring and Care Market 2020 Size, Growth, Trends, Industry Share, Emerging Technologies &Top Players by Abbott, Baxter, Boston Scientific, Medtronic, Omron Healthcare, BioTelemetry

Legal Marijuana Market Size, Growth Analysis 2020, Industry Statistics, Value, Demand, Future Trends, Top Leaders-VIVO Cannabis, Dr. Hemp Me, QC Infusion, Green Roads, Royal CBD, CBD Oil Europe, King CBD

CBD Oil Industry 2020-Market Size, Share, Demand, Growth, Global Top Companies-Canazil, Kazmira, Spring Creek Labs, Isodiol International, HempLife Today, Hemp Oil Canada, Medical Marijuana

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Excerpt from:
Cancer Gene Therapy Market 2021 Global Industry Size, Share, Growth, COVID-19 Impact Analysis, and Drivers Analysis Research Report 2027|...

Recommendation and review posted by Bethany Smith

INTRODUCTION Given their ability to treat a wide range of clinical conditions, advanced therapy medicinal products, including cell and gene therapies, have revolutionized the delivery of healthcare.

New York, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell Therapy Packaging Products and Services Market by Type of Therapy, Package Engineering Design, Scale of Operation and Geography : Industry Trends and Global Forecasts, 2021-2030" - https://www.reportlinker.com/p06130493/?utm_source=GNW Presently, more than 30 cell-based therapy products have received marketing approvals across various geographies, while more than 1,000 therapeutic candidates are under clinical evaluation. Considering the lucrative investment opportunity within this domain, several investors are actively supporting ongoing / future product development programs in this upcoming field of pharmacological interventions. In fact, there has been a 240% increase in investment activity, in terms of capital amount invested, between 2019 and 2020. However, the ultimate success of cell therapies is dependent on the safe and timely delivery of viable doses of therapeutic cells to the right patient. In this context, it is worth highlighting that drug product manufacturing, packaging and logistics operations involving cell therapies are both complex and challenging. Moreover, in order to ensure the stability of such products across the supply chain, specific temperature conditions (cryogenic, ambient or refrigerated) are required, in addition to specialized packaging material. Considering that most cell therapies are personalized, it is imperative that errors in labeling are avoided at all costs.

Given the need for costly and specialized equipment and the complexities associated with handling cell-based therapy products, innovators in the healthcare industry are likely to involve contract service providers for their drug product production, packaging and transportation requirements. Over time, regulators across the world, including the US Food and Drug Administration (FDA) and the International Air Transport Association (IATA), have established guidelines for the packaging, storage and transport of cell therapies. Since CMOs / CDMOs with the necessary capabilities to handle cell therapies are also likely to have established processes that comply with the current acceptable standards across different global regions, it is better for therapy developers to strategically partner with the aforementioned players instead of focusing on developing in-house capabilities. Presently, close to 60 companies claim to be offering cell therapy packaging services and associated products. In fact, it is estimated that close to 30% of drug substance and drug product related operations of advanced therapy medicinal products are already outsourced to capable CMOs / CDMOs. Further, over the last few years, several service providers have also forged strategic alliances among themselves, in order to further expand existing capabilities and augment their respective service offerings. Given the rising trend of outsourcing in the healthcare industry, and the ongoing efforts of service providers to further improve their portfolios, we believe that the cell therapy packaging products and services market is likely to evolve at a steady pace in the next few years.

SCOPE OF THE REPORT The Cell Therapy Packaging Products and Services Market by Type of Therapy (T-cell Therapies, Dendritic Cell Vaccines, Stem Cell Therapies, NK Cell Therapies and Other ATMPs), Package Engineering Design (Primary and Secondary Packaging), Scale of Operation (Clinical and Commercial) and Geography (North America, Europe, Asia Pacific and Rest of the World) , 2021-2030 report features an elaborate study of the current scenario and future opportunity within the cell therapy packaging products and services market. In addition, the report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. Amongst other elements, the report includes: An overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis based on their year of establishment, company size, location of headquarters, package engineering design (primary and secondary), type of packaging (active and passive), packaging material (dry ice and liquid nitrogen), type of passive system used, temperature ranges supported, type of cells handled and additional services offered. A detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bags, vials, shipping container and others), container fabrication material (plastic and others), storage temperature conditions, type of cells packed and usability of containers. In addition, the chapter highlights analysis of cell therapy packaging product provider(s), based on various parameters such as year of establishment, company size and location of headquarters and key players. An in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported) service portfolio (type of additional services offered) and company size (small, mid-sized and large companies). An analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period, 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service covered and geographical location of players involved in a partnership. A list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate). A case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies. Detailed profiles of the key players offering cell therapy packaging services and products. Each profile includes a brief overview of the company, details on cell therapy service portfolio, information on cell therapy packaging product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to estimate the existing market size and future growth potential of the cell therapy packaging providers market. We have provided informed estimates on the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented across [A] type of therapy (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK cell therapies and other advanced therapy medicinal products), [B] package engineering design (primary and secondary packaging), [C] scale of operation (clinical and commercial) and [D] geography (North America, Europe, Asia Pacific and Rest of the World)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

KEY QUESTIONS ANSWERED Who are the leading players offering cell therapy packaging services and products? What are the key considerations and challenges associated with cell therapy packaging? Which partnership models are commonly adopted by stakeholders engaged in this industry? Which players are likely to partner with cell therapy packaging service and product providers? What factors are likely to influence the evolution of the cell therapy packaging service providers market? What are the likely future trends in cell therapy packaging services market? How is the current and future opportunity likely to be distributed across key market segments?

RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been validated from multiple sources of information.

The secondary sources of information include: Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market till 2030, the report also provides our independent views on various non-commercial trends emerging in this industry. The opinions are solely based on our knowledge, research and understanding of the relevant market trends gathered from various secondary sources of information.

CHAPTER OUTLINES Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell-based therapy manufacturing market and its likely evolution in the short to mid-term, and long term.

Chapter 3 provides a general introduction to the pharmaceutical filling and packaging, including information on types of pharmaceutical packaging. The chapter lays emphasis on cell therapy packaging, primary and secondary packaging of cell therapies. In addition, it discusses the key considerations and challenges associated with cell therapy packaging.

Chapter 4 features an overview of the current market landscape of cell therapy packaging services providers, including a detailed analysis on the year of establishment, company size and location of headquarters. In addition, the chapter highlights the analysis on the package engineering design (primary and secondary), type of packaging (active and passive), packaging material (dry ice and liquid nitrogen) and type of passive system used. Further, the chapter also presents analysis on temperature ranges supported, type of cells handled and additional services offered.

Chapter 5 fpresents a detailed assessment of the current market landscape of cell therapy packaging products, providing information on type of packaging container (bags, vials, shipping container and others), container fabrication material (plastic and others), storage temperature conditions, type of cells packed and usability of containers. In addition, the chapter highlights analysis of cell therapy packaging product provider(s), based on various parameters such as year of establishment, company size and location of headquarters and key players.

Chapter 6 includes profiles of the key players offering cell therapy packaging services and products. Each profile includes a brief overview of the company, details on cell therapy service portfolio, information on cell therapy packaging product portfolio, recent developments and an informed future outlook.

Chapter 7 presents in-depth competitiveness analysis of cell therapy packaging service providers based in different geographies, by taking into consideration the service strength of a company (based on its experience), packaging portfolio (package engineering design, type of packaging, type of packaging material and temperature ranges supported) service portfolio (type of additional services offered) and company size (small, mid-sized and large companies).

Chapter 8 provides an analysis of the various partnerships established between cell therapy packaging providers and cell therapy developers, during the period, 2016-2021. It includes a brief description of various types of partnership models (namely service alliance, technology / platform integration agreement, merger and acquisition) adopted by stakeholders engaged in this domain. It is worth mentioning that the data captured during our research was analyzed based on several parameters, such as year of partnership, type of partnership, purpose of partnership, type of service covered and geographical location of players involved in a partnership.

Chapter 9 presents a list of more than 250 cell therapy developers anticipated to partner with cell therapy packaging providers, which have been shortlisted on the basis of developer strength (based on company size), type of therapy and pipeline maturity (based on stage of development of drug candidate).

Chapter 10 features a case study highlighting the companies that claim to have the required expertise and capabilities for development and manufacturing of cell therapies, along with the information on their year of establishment, company size, location of headquarters and location of manufacturing facility. In addition, the chapter presents analysis on type of cells manufactured, source of cells, scale of operation and manufacturing capabilities / services of the aforementioned companies.

Chapter 11 presents a detailed market forecast analysis, providing insights on the likely growth of continuous manufacturing equipment providers market for the period 2021-2030. In addition, the chapter presents the likely distribution of the projected future opportunity based on type of therapy (T-cell therapies, dendritic cell vaccines, stem cell therapies, NK cell therapies and other advanced therapy medicinal products), package engineering design (primary and secondary packaging), scale of operation (clinical and commercial) and geography (North America, Europe, Asia Pacific and Rest of the World).

Chapter 12 is a summary of the overall report, which presents the insights on the contemporary market trends and the likely evolution of cell therapy products and services market.

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix that provides the list of companies and organizations mentioned in the report.Read the full report: https://www.reportlinker.com/p06130493/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Visit link:
Cell Therapy Packaging Products and Services Market by Type of Therapy, Package Engineering Design, Scale of Operation and Geography : Industry Trends...

Recommendation and review posted by Bethany Smith

Senescent immune system cells are potentially among the most harmful of all senescent cells because they spread tissue damage and rapid aging across other body organs and systems. That is what a team of NIA-supported scientists at the University of Minnesota Medical School discovered through research using a mouse model that accelerated immune system aging by hindering DNA repair. The team recently published these findings in Nature.

Cellular senescence is defined as a condition in which a cell no longer has the ability to proliferate. These damaged cells resist the bodys usual system of disposal and then linger, excreting chemicals that spread inflammation and damage to neighboring normal cells.

For this study, the team made a cell-specific knockout of the gene Ercc1, which controls a protein crucial for DNA repair. Ercc1 was removed in blood-based young stem cells that normally develop into white blood cells cells important for immunity but the gene was expressed normally in all other tissues. This enabled the research team to understand whether senescence in the immune system affects other cells in the body. The engineered mice seemed healthy up until their adulthood (around three months) but then aged rapidly. At age five months, they biologically resembled 2-year-old mice, which is approximately equivalent to an 80-year-old human.

The prematurely older mice had a host of age-related conditions such as osteoporosis; visual and hearing impairment; and high blood pressure, even though the change was limited to cells of the immune system. The senescent immune system cells also spread age-related damage to other organs and tissues in the body, including the liver, lungs, and kidneys. Without the Ercc1 gene, the mice had lost much of their ability to repair DNA in these immune cells and thus experienced a build-up of inflammation and damage in other tissues.

The scientists saw this rapid aging and spread of damage throughout the body as evidence that senescent immune system cells are potentially among the most dangerous of all senescent cell types in the aging body. Because immune cells circulate throughout the body, when they become senescent, they can easily expose a wider range of organs and tissues to inflammation and other damaging factors, unlike more stationary senescent cells such as those in the skin.

The team also studied and confirmed some mechanisms that contribute to senescence in the immune system. First, they showed that senescent immune cells trigger and drive senescence elsewhere in the body by observing senescence triggered across systems in young mice after transplanting spleen cells from old mice into them. Next, they observed that when immune cells from young healthy mice were transplanted into older mice, senescence was reduced, providing further evidence that old immune cells lose function. The scientists also used the drug rapamycin, which tamps down the inflammatory secretions from senescent cells, to show that reducing senescence improved immune function.

While the field of senescence is still very far from any reliable application for humans, the investigators aim to pursue follow-up efforts to pinpoint a precise type of senolytic a drug that selectively clears senescent cells from the body to target reducing immune system senescence as a potential future intervention to aid healthy aging. They hope to conduct additional studies in this realm to find new immune system biomarkers to help gauge which people are at the highest risk for senescence-related tissue damage and faster aging, and thus would be candidates to benefit from senolytic therapies.

This work was supported by NIH grants P01 AG043376, RO1 AG063543, R56 AG059676, U19 AG056278, P01 AG062413, R56 AG058543 and R01 AG044376.

Reference: Yousefzadeh, Matthew J et al. An aged immune system drives senescence and ageing of solid organs. Nature vol. 594,7861 (2021): 100-105. doi:10.1038/s41586-021-03547-7

Here is the original post:
Senescent immune cells spread damage throughout the aging body - National Institute on Aging

Recommendation and review posted by Bethany Smith

Moms IL-6 rewires babys gut immunity

Most infections that occur during pregnancy are mild and transient. However, whether such pathogen encounters can shape the long-term trajectory of the offsprings immune system remains unclear. Lim et al. infected pregnant mice with the common food-borne pathogen Yersinia pseudotuberculosis (YopM) (see the Perspective by Amir and Zeng). Although the infection was maternally restricted and short-lived, the offspring harbored greater numbers of intestinal T helper 17 cells into adulthood. Interleukin-6 (IL-6) mediated this tissue-restricted effect by acting on the fetal intestinal epithelium during development. Although offspring from mothers infected with YopM or injected with IL-6 showed enhanced resistance to oral infection with Salmonella Typhimurium, they also exhibited higher susceptibility toward enteric inflammatory disease.

Science, abf3002, this issue p. eabf3002; see also abl3631, p. 967

One fundamental property of the immune system is its ability to develop memory of previous encounters, resulting in enhanced responsiveness to subsequent challenges. This phenomenon includes not only the adaptive immune system but also innate cells and tissue stem cells. The concept of host imprinting by infection leading to altered responses to subsequent challenge is of particular interest in the context of pregnancy, which represents a fundamental developmental window for the immune system.

Most infections encountered by mammals, including those experienced during pregnancy, are mild and transient. How these infections shape offspring tissue immunity and tissue predisposition to inflammatory disorders in the long term remains to be addressed.

Infection of timed-pregnant dams (day 10.5) with an attenuated strain of the food-borne pathogen Yersinia pseudotuberculosis (yopM) was transient and maternally restricted. Adult offspring of previously infected dams harbored a higher number of T helper 17 (TH17) cells but no other cell subsets in the small and large intestinal lamina propria. No changes were observed at other barrier tissues. Transfer of transgenic T cells specific for a commensal antigen revealed that maternal infection affected the offspring intestinal milieu in a manner that enhanced TH17 cell reactivity toward the microbiota. Cross-fostering experiments demonstrated that the increased TH17 cells resulting from maternal infection was imprinted in utero. Among various inflammatory mediators, the cytokine interleukin-6 (IL-6) was significantly increased in the serum of dams infected with yopM. Injection of IL-6 alone to pregnant dams significantly increased TH17 cell numbers within the guts of offspring. Conversely, blockade of IL-6 in infected dams prevented this increase in offspring. Furthermore, injection of IL-6 to germ-free pregnant dams and conventionalization of their offspring after weaning revealed that prenatal establishment and postnatal maintenance of IL-6mediated tissue imprinting are independent of the maternal microbiota but allow the offspring to mount enhanced TH17 cell responses to postnatal microbiota exposure.

IL6RA was expressed in all fetal intestinal epithelial cells, and specific deletion of IL6RA from epithelial cells significantly reduced Th17 responses within the gut of offspring from IL-6exposed dams. Using complementary approaches, including assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) and single-cell RNA sequencing, we found that increased IL-6 during pregnancy had immediate effects (on fetal cells) and long-term effects (in the adult offspring) on epithelial stem cell chromatin accessibility and downstream epithelial cell function, particularly increased expression of genes encoding for antigen presentation machinery and antimicrobial peptides.

Altered epithelial activation status suggested the possibility that this phenomenon may be associated with enhanced antimicrobial defense. To address this, we used an acute model of oral infection with Salmonella Typhimurium. Offspring from dams previously infected with yopM or injected with IL-6 during pregnancy developed enhanced resistance to Salmonella oral infection and dissemination. No differences were observed in controlling cutaneous Candida albicans infection, further supporting the idea that maternal imprinting of offspring is restricted to the gut compartment. However, enhanced exposure to IL-6 during pregnancy was associated with enhanced gut pathology in the context of nave T cell transfer and dextran sulfate sodiummediated colitis.

Our work proposes that a transient, mild infection encountered during prenatal development can impose lasting alterations to gut epithelial stem cells, resulting in an altered threshold of activation and enhanced resistance to gut infection. The impact of maternal infection was tissue specific and predominantly mediated by a single cytokine, IL-6, acting on epithelial stem cells during fetal development. Although this phenomenon can be coopted by the fetus to develop optimal immune fitness, altered offspring immunity imposed by maternal infection comes at the cost of enhanced susceptibility to mucosal inflammation.

The direct response of fetal intestinal epithelial cells to IL-6 during maternal infection confers an enduring epigenetic memory to adult intestinal epithelial stem cells. As such, offspring epithelial cells exhibit enhanced reactivity toward the microbiota and heightened ability to control oral infection. However, these responses come at the cost of greater predisposition to gut inflammation.

The immune system has evolved in the face of microbial exposure. How maternal infection experienced at distinct developmental stages shapes the offspring immune system remains poorly understood. Here, we show that during pregnancy, maternally restricted infection can have permanent and tissue-specific impacts on offspring immunity. Mechanistically, maternal interleukin-6 produced in response to infection can directly impose epigenetic changes on fetal intestinal epithelial stem cells, leading to long-lasting impacts on intestinal immune homeostasis. As a result, offspring of previously infected dams develop enhanced protective immunity to gut infection and increased inflammation in the context of colitis. Thus, maternal infection can be coopted by the fetus to promote long-term, tissue-specific fitness, a phenomenon that may come at the cost of predisposition to inflammatory disorders.

Read the original post:
Prenatal maternal infection promotes tissue-specific immunity and inflammation in offspring - Science Magazine

Recommendation and review posted by Bethany Smith

A patient recently came in to our dermatology clinic with a rash and a story similar to so many others. He had been out camping with friends a few days earlier and helped carry some logs to stoke the fire. Little did he know he was going to pay for lending a helping hand. A couple days later, red patches appeared on his forearms and chest, which soon began to itch miserably and form water blisters.

If you have ever spent any time outdoors in the woods, working in the yard, even at the edges of a playground maybe youve experienced something similar after encountering poison ivy. Its not easy to forget.

Poison ivy is found everywhere in the continental U.S., mostly in Eastern and Midwestern states. Unfortunately for us humans, it is a hardy plant that can grow under many different conditions. Its favorite places are in wooded areas, gardens and roadsides with partial shade or full sunlight.

And despite being a nuisance to people, poison ivy is an important member of the ecosystem. Its leaves, stems and berries are food for animals, and its vines can be shelter for small animals like toads and mice, even helping them climb trees. Climate change is turning out to benefit poison ivy, allowing for larger and more irritating plants.

You can usually spot poison ivy by its infamous three dull or glossy green leaves coming off a red stem. Sometimes there are flowers or fruits coming off the end of a branch.

Despite its name, poison ivy is not poisonous. It carries an oily sap on its leaves and stems called urushiol, which is irritating to most peoples skin. In fact, 85% to 90% of people are allergic to poison ivys urushiol to some degree, while the rest lack sensitivity to this oil. You can occasionally see the urushiol oil as black spots on poison ivy leaves. Urushiol is what gives poison oak and poison sumac their evil power, too.

Touching poison ivy directly is obviously a bad idea. You can even get into trouble by touching clothing, pets or anything else that has brushed against the plant and picked up some of the urushiol. If a contaminated object isnt cleaned, the urushiol will remain lying in wait it can still cause a rash after hours, days or even years. Another danger is smoke from burning poison ivy, which can also affect your skin, as well as your nose, mouth, windpipe and lungs if you breathe it in.

Poison ivys rash can come in many forms, from small, red bumps to blisters or red patches. Whichever way it shows up, it is almost always mindbogglingly itchy.

When you get poisoned, you wont know right away. It can take anywhere from four hours to 10 days for the rash to appear, depending on how much urushiol gets on your skin, how sensitive you are to it and how many times you have been exposed to poison ivy previously.

Between exposure and itchy anguish, your body goes through a complex identification and reaction process. When the oil gets into your skin, your immune systems sensor cells recognize urushiol as foreign to your body. These sensor cells then call in protector cells to the area, warning them of the invasion. The protector cells defend your body against the intruder by attacking the urushiol in the skin. Unfortunately, some of your bodys normal skin cells are casualties of this war, which is what leads to the itchiness and swelling of a poison ivy rash.

Your protector cells will then sit near the skin for many years and stand guard for urushiol if it ever shows up again. If it does, they remember having encountered this bad guy before, and their response is often faster and more powerful than the first time.

This rash is a type of allergic contact dermatitis in the same family as the rashes some people get from wearing jewelry or metal belt buckles or from using certain fragrances or cosmetics.

The saying leaves of three; leave them be highlights the best strategy to prevent poison ivy: avoidance. But if you do happen to come into contact with poison ivy, the first step should always be to remove and wash any clothing that has touched the plant. Gently but thoroughly wash your skin immediately with soap and water. It can also help to clean under your fingernails and cut your nails short to prevent the urushiol from spreading if you scratch your skin.

Allergic contact dermatitis from poison ivy almost always results in a rash that usually lasts two to three weeks before it completely goes away.

[Get The Conversations most important coronavirus headlines, weekly in a science newsletter]

It will eventually clear up on its own, but you can try some over-the-counter and home remedies to keep the itchiness and spread of the rash at bay. The blisters that form are not infected and do not normally require antibiotics. If you scratch though and it can be very hard to resist open skin can get infected.

To reduce itchiness, cool, wet compresses can help, as can a soak in a cool bath with baking soda or oatmeal bath products. Calamine lotions or creams containing menthol can also cut the itch a bit. Over-the-counter cortisone cream or ointment can be used for the first several days after contact with poison ivy to quiet down your bodys reaction and keep the rash from getting severe. Taking antihistamines like diphenhydramine at night can slightly reduce itchiness and it has the benefit of helping you sleep better.

Seeing your doctor usually is not necessary for a poison ivy rash unless it spreads over large areas, becomes infected, lasts more than three weeks or is a rare extreme case that affects your breathing.

The best offense is a good defense. When youre in the great outdoors, be careful what you touch and, when in doubt, if it has leaves of three, leave them be.

Read more:
Poison ivy can work itchy evil on your skin here's how - The Conversation US

Recommendation and review posted by Bethany Smith

Work-from-home, double taps, left swipes, binge-watch and reel challenges are a few of the many Internet jargons which have become our constant companions. Thanks to the pandemic and restrictions on moving freely, our work and playtime are both equal to screen time. And as satisfying and relaxing as those cat jade rolling videos might be, increasing your screen time is doing no favours to your skin.

Unlike UV rays which are invisible to the eye, High Energy Visible Light (HEV) or blue light emitted from electronic screens is visible to us. It increases the oxidative damage to our skin and is said to make it age faster. Melasma, skin discolouration, pigmentation, collagen breakdown and wrinkle formation are a few of the skin issues that might be a result of or worsen due to blue light, which is found in sun rays too. While we are yet to know the extent to which blue light from screens can affect our skin due to free radical damage, we do know that using antioxidant-rich products can help you tackle this concern. So if your skincare already includes antioxidants such as vitamin C and E, you are in the zone. And if you use mineral sunscreens that contain zinc oxide and titanium dioxide, its doing double the work by blocking UV rays and blue light to an extent. So if you use vitamin C, ferulic acid and top it with sunscreen, your skin is pretty walled up against all kinds of light damage.

Switching your phone to night mode will help your case, but including these or similar products in your routine will only do more good and no harm.

More here:
7 products that will arm your skin against blue light damage - VOGUE India

Recommendation and review posted by Bethany Smith

Nature of Things launched the Elemental Skincare collection in April, which features a complete ... [+] four-step facial routine.

As the summer season winds down, now is the perfect time to start thinking about how to streamline your skincare routine to keep that sun-kissed glow and stay protected from the elements all year long.

I might be biased (and, yes, I test cannabis products as part of my job) but over the past few years, Ive transitioned to an all-CBD-based face and body regimen (with the exception of Biologique RechercheLotion P50 and EltaMD sunscreen). The result? My clearest and healthiest complexion to date.

With BDSAs recent trend report forecasting the CBD beauty segment of the market to reach $720 million this year alone a 60% increase over 2020 and representing just 10% of the total CBD market the number of new brands and product launches to consider buying often at a high price tag is overwhelming.

Whether you are looking to make a complete switch to CBD or want to try just one step at a time, here are the nine best cannabis beauty launches of 2021 (so far) to help narrow your search each tried-and-tested in the challenging and drying environment of the high alpine.

*Note: This list is in alphabetical order, not ranked and will continue to get updated with new product launches through December 2021.

Vitamin C + Squalane + CBD Skin Elixir

This antioxidant-rich formula combines three superstar ingredients vitamin C, squalane and CBD to create a natural skin brightener, which targets dark spots and reduces signs of aging. Best used after moisturizer and under makeup in your morning routine, Botanika Lifes newest serum is infused with 1,000 milligrams of full-spectrum CBD extract, which helps with hydration and restore natural radiance. And dont forget to layer with sunscreen after you apply to improve sun protection.$95, botanikalife.com

Look Alive Face Moisturizer

For celebrity co-founder Kristen Bell, the havoc wreaked on her skin from the normal stresses of the day was the inspiration in creating Happy Dances debut face moisturizer. Formulated as a first line of defense barrier, this whipped, hydrating creme is light on skin, but heavy on hydration. Infused with 150 milligrams of CBD extract, its also powered by avocado oil, bisabolol with a ginger blend andfour types of hyaluronic acid. Plus, its been ophthalmologist-tested (for safe use around the eyes) and available at a more accessible price point than most CBD-based moisturizers on the market.$29, doahappydance.com

Bleu Body Wax

Khus + Khus founder Kristi Blustein is an Ayurvedic specialist, aromatherapist and herbalist experience that makes her modern herbal fusion mission stand apart among the crowded CBD beauty product space.Released earlier this year, the Bleu Body Wax is a concentrated pomade thats solid at room temperature and when warmed up in your hands, liquifies for smooth application. Each jar is packed with 225 milligrams of broad-spectrum CBD complemented by coconut, baobab seed, Marla and beeswax with essential oils like tiara flower and blue yarrow to perfume the body naturally. $77, khus-khus.com

The Rose Absolute Oil

So its not technically a CBD product pick, but Lab to Beauty turned to another cannabis compound for a second skincare collection. CBG (cannabigerol) is just one of more than 120 identified cannabinoid compounds found in the plant genus. It is known to calm inflammation, reduce blemishes, purify pores, balance sebum production and assist with cellular turnover. Concocted with Bulgarian rose extract, golden jojoba oil, moringa, immortelle and rosehip oil, this luxurious and healing formula works to fight aging, improve elasticity and deliver a youthful plump. Use The Rose Absolute Oil nightly after cleansing and toning or under your favorite foundation to boost brightness. $145, labtobeauty.com

Bump & Smooth CBD Body Serum

Lord Jones recent release is the answer to one of the most common skin issues: those mysterious mini-bumps and rough patches often inflicted by too much time in the sun. This potent resurfacing serum delivers a non-abrasive chemical exfoliation experience that reduces bumpiness and reveals smoother, brighter-looking skin thanks to 200 milligrams of full-spectrum CBD extract blended with bisabolol, hyaluronic acid, ceramides and squalane. Whether you suffer from Keratosis Pilaris (KP) or are just looking for a refresh to dull skin, Lord Jones Bump & Smooth CBD Body Serum gently removes dead cells to reveal whats underneath. $60, lordjones.com

Facial Essence

Beloved for its body care and bath immersion portfolio of products, Nature of Things introduced a skincare line earlier this year featuring a cleanser, toner, moisturizer and mask (face stone optional). While the entire four-step routine is remarkable, the Balancing Facial Essence has remained in my medicine cabinet because of its soothing, hydrating and dewy result from pure ingredient extracts like broad-spectrum CBD, Swiss apple stem cells, Korean kombu algae and French thermal water. Bonus benefits include new skin cell growth, refined pores and free radical protection. $95, natureofthings.com

Beyond Body Oil

Supercharged with 600 milligrams of hemp CBD oil per generous-sized bottle, Primas latest addition to its lineup goes way beyond your average body oil. Plant actives including omegas, phenols, antioxidants and fatty acids are meticulously combined with magnesium and helichrysum in this soothing, therapeutic formula, which actually repairs and restores the skin while also improving tone and texture. Pro-tip: Keep it in your shower for application to breathe in the aromatic blend of clove, geranium and citrus and lock in most moisture just before getting out. $56, prima.co

Hydrating Petal Cream

Best-selling CBD beauty brand Saint Jane has done it again with its first-ever face cream (previous award-winning releases in the category include The C-Drops, Bright Repair Eye Cream and Luxury Beauty Serum). Founder Casey Georgeson spent more than a year searching for the flower thats best for skin hydration and hibiscus, known as natures Botox, was ultimately selected for its efficacy in firming and restoring elasticity to the skin. Blended with 1% pure hyaluronic acid, the lightweight Hydrating Petal Cream is a joy to apply, absorbing quickly into the skin and leaving the face with a dewy finish that lasts all day. $68, saintjanebeauty.com

Glow Drops

They say beauty comes from within, so incorporating a CBD-based tincture into your regimen is a secret weapon in supercharging your skin. As the first-to-market beauty-focused elixir, Undefined Beautys Glow Drops can also be mixed into any moisturizer to achieve an extra shine. Paired with adaptogens ranging from mucuna (mood-boosting) and cordyceps (anti-inflammatory) to guava leaf (immunity-boosting) and astaxanthin (antioxidant), the tasty tangerine formula is an easy way to simplify your daily dose whether taken under the tongue or added to a beverage. Each full-size bottle includes over 600 milligrams of CBD, CBD and CBC (cannabichromene) sourced from a certified-organic, female-founded regenerative hemp farm. $48, undefinedco.com

Read the original post:
The Best New CBD Skincare Products Of 2021 (So Far) - Forbes

Recommendation and review posted by Bethany Smith

One of the key factors fueling the growth of the global hormone replacement therapy market is increasing acquisitions. Pfizer Inc., a pharmaceutical firm headquartered in the United States, combined with OPKO Health Inc., a business based in the U.S., in 2014 to create a long-acting growth hormone (hGH-CTP) and novel therapies for growth hormone deficient individuals. hGH-CTP is more convenient since patients just require one injection each week instead of daily dosages. In the U.S. and Europe, hGH-CTP has been designated as an orphan medication for children and adults with growth hormone deficiencies.

The expansion of the global hormone replacement therapy market is projected to be aided by a strong pipeline. In 2017, Novo Nordisk A/S, a Danish firm, completed phase 3 clinical studies for Somapacitan. This medication is used to treat adult testosterone deficiency.

FREE | Request Sample is Available @https://www.coherentmarketinsights.com/insight/request-sample/2079

*The Sample only consist ofTable of Content (ToC).Research Frameworkof the actual report.Research Methodologyadopted for it.

Major Company Profiles Covered in This Report:Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

The market for hormone replacement treatment is projected to expand due to the rising prevalence of various chronic diseases.

The market for hormone replacement treatment is projected to expand due to the rising prevalence of hypogonadism in adult males throughout the world. Hypogonadism affects 2.1 percent to 12.8 percent of middle-aged men, according to the European Association of Urologys 2016 study. In Europe, the prevalence of low testosterone and hypogonadism symptoms in males aged 40 to 79 ranges from 2.1 percent to 5.7 percent.

The expansion of the global hormone replacement therapy market is projected to be aided by easier access and government assistance for research and development efforts. NGOs such as the National Gaucher Society provide financial assistance to patients who require expensive insulin replacement treatment.

Request Free research report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/2079

Companies are concentrating their efforts on creating generic versions of numerous medications for the treatment of diseases that are more common in women, such as hypothyroidism. On July 24, 2017, Teva Pharmaceutical Industries Ltd. introduced a generic version of Vagifem, 10 mcg, in the United States. Estradiol vaginal inserts are a kind of oestrogen used to treat atrophic vaginitis caused by menopause.

Furthermore, Mylan N.V. received FDA clearance for its Abbreviated New Medication Application (ANDA) for Estradiol Vaginal Cream USP, 0.01 percent on December 29, 2017, and therefore marketed the drug in the U.S. This cream is the first generic alternative to Allergans Estrace Cream, which is used to treat vulvar and vaginal atrophy.

Mylan is one of the few firms that sells Estradiol in cream, gel, transdermal patch, and tablet form. This will benefit both healthcare personnel and patients, as well as ensuring the businesss long-term viability.

Major companies contributing in the global hormone replacement therapy market are Pfizer Inc., QuatRx Pharmaceuticals, Mylan N.V., Abbott Laboratories, Amgen, Inc., Novartis AG, Eli Lilly and Company, Bayer AG, Merck KgaA, Teva Pharmaceutical Industries Ltd., and Novo Nordisk A/S.

Inquire more about this report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2079

Some Notable Offerings by Coherent Market Insights Report on Hormone Replacement Therapy market:

We will provide you an analysis of the extent to which this Hormone Replacement Therapy market research report acquires commercial characteristics along with examples or instances of information that helps you to understand it better.

We will also help to identify customary/ standard terms and conditions, as offers, worthiness, warranty, and others.

Also, this report will help you to identify any trends to forecast growth rates.

The analyzed report will forecast the general tendency for supply and demand.

Also, Research Report Examines:

Competitive companies and manufacturers in global market

By Product Type, Applications & Growth Factors

Industry Status and Outlook for Major Applications / End Users / Usage Area

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Follow this link:
[PDF] Hormone Replacement Therapy Market to Reflect Steady Growth and Future Scope UNLV The Rebel Yell - UNLV The Rebel Yell

Recommendation and review posted by Bethany Smith

Ethereum co-founder Vitalik Buterin is on a mission to make humans immortal. Buterin, 27, proposes the idea that aging is an engineering problem.

He is not alone in his combined interest in Bitcoin and biohacking. Famous biomedical aging researcher Aubrey de Grey, Xanadu architect and Agoric chief scientist Mark Miller, Bitcoin Cash billionaire Roger Ver and former chief technology officer of Coinbase and a16z general partner Balaji Srinivasan, are all fascinated by the pursuit of longevity.

De Grey recently helped advise a decentralized collective funding longevity research. He says:

I have been gratified since the beginning of blockchain to see the enormous fanbase that I and the longevity movement have in there.

Miller, alongside his engineering hall-of-fame accomplishments, is a senior research fellow at the Foresight Institute, a not-for-profit founded in 1986 with the aim of advancing technology for the long-term benefit of life.

Im very much involved in this new world of crypto commerce, often referred to as the blockchain sector, he says. Im very hopeful about that as creating an ecosystem in which secure software will dominate because insecure software results in massive losses quickly, with no recourse.

Srinivasans Twitter bio describes his vision as: Immutable money, infinite frontier, eternal life. #Bitcoin. Srinivasan states that the ultimate purpose of technology is to eliminate mortality and life extension is the most important thing we can invent.

Blockchain communities are clearly excited about longevity. But what does cryptocurrency have to do with life extension, and where might this future be headed?

It turns out that the link between crypto and cryogenics stretches back to core contributors, and the Cypherpunks mailing list and its links to transhumanist groups, including the first person to transact Bitcoin with Satoshi, Hal Finney.

Crypto philanthropists are donating significant wealth to this area, which is typically difficult to garner mainstream support for. They may be the only people on the planet optimistic enough to fund tech that currently only exists in sci-fi novels.

According to Buterin, longevity is a battle worth fighting for. Buterin donated $25 million in SHIB cryptocurrency tokens to the Future of Life Institute in June 2021 and has donated over $350,000 to the SENS Research Foundation to reimagine ageing.

He discussed the topic in recent podcast interviews with the likes of Lex Fridman and Tim Ferriss saying that life extension is definitely really important to me.

I think I hope to see the concept of seeing your parents and grandparents die just slowly disappear from the public consciousness as a thing that happens over the course of half a century.

Buterin has emphasized his adherence to the moral philosophy of effective altruism. This value, known to transhumanists as the moral urgency of saving lives, is perhaps what motivated his donations of dog coins to both COVID-19 relief in India and life-extension.

Just even the process of aging turning into something that just becomes reversible and it being a regular thing for people to live one and a half, two centuries and then go even further from there, Buterin states.

Pinned in Buterins Twitter is an essay called The Fable of the Dragon Tyrant by professor Nick Bostrom, director of the Future of Humanity Institute. It argues that allowing death from old age is unethical. If you view aging as a disease, the urgency to support the transhumanist project also makes sense.

While we still lack effective and acceptable means for slowing the aging process, we can identify research directions that might lead to the development of such means in the foreseeable future, states Bostrom. The key to freeing humanity from the dragon tyrant of aging, is funding. The new riches from crypto are key.

Bitcoin.com founder Roger Ver has already signed up to be cryogenically frozen. Rather than investing in cryptocurrency stuff, I want to focus on the extreme life extension technologies, because if you die, you cant enjoy your life anymore, Ver told Cointelegraph. Hes so confident in the tech, he even considered being cryogenically frozen as a legitimate alternative to going to prison in 2002.

DAOs are also taking part in this life extension renewal. There is a strong overlap of crypto people and longevity people, Vincent Weisser, core team member at VitaDAO tells Cointelegraph. VitaDAO funds longevity research and exceeded its initial token raise funding target of $490,000 in June 2021.

Now, they are working with popular blockchain crowd-funding platform Gitcoin to include a future funding category for longevity and life extension.

Transhumanist philanthropy and funding at scale holds the potential to significantly impact longevity research and the transhumanist project.

Transhumanism is a loosely defined movement that promotes the use of technology to enhance the human condition. This includes information technology, genetic engineering, and artificial intelligence for radical extension of human lifespan, augmentation of physical and intellectual capacities, space colonization, and super-intelligent machines.

The goal is not just life extension, but more, to the point of becoming superhuman. Although the transhumanist pursuit of post-humanity is often thought of as medical, the gambit of transhumanist technologies includes economic and social institutional design and cultural development.

Like crypto communities, transhumanism is grounded in a vision of evolution and individual freedom of choice. In practice, this leads to a sense of personal responsibility for contributing to solutions, such as biohacking or making provisions for being cryogenically frozen and one day hopefully reanimated. The goal of the transhumanist project for society is one based on freedom in determining social arrangements, enabled by self-generating systems and spontaneous order. This description of perpetual, open systems is similar to blockchain.

Not everyone thinks eternal life, or the philosophy underpinning it, is a good idea. Political economist Francis Fukuyama calls transhumanism the most dangerous idea in the world and argues it is a strange libertarian movement whose crusaders want nothing less than to liberate the human race from its biological constraints. He lists the risks of the fraught nature of humankind to want to live forever, the effects on equality between the haves and the have nots, and that the essence of humanity is mortality. Yet, transhumanism has a long history in crypto communities.

Transhumanist values are reflected in the ideological underpinnings of blockchain communities around anarchy and autonomy, self-improvement, and a long-term mindset.

Transhumanist ideas have long existed in the technology communities that pioneered the core tenets of public blockchains. For example, cryptography pioneer Ralph Merkle (inventor of public key distribution and Merkle trees) considered himself a transhumanist, publishing on such matters as The Molecular Repair of the Brain.

Furthermore, there was substantial cross-pollination of ideas between the Cypherpunks mailing list, which discussed ideas on privacy and digital cash throughout the 1990s and 2000s in the lead-up to the invention of Bitcoin in 2008, and the Extropian mailing list.

Extropy is the extent of a systems intelligence, information, order, vitality, and capacity for improvement. According to 1998s Principles of Extropy published by president of the Extropy Institute, Max Moore, extropians are those who seek to increase extropy. The core principles, refined in The Extropist Manifesto in 2010, are endless eXtension, meaning perpetual growth and progress in all aspects of human endeavor; transcending the restrictions of authoritarianism, surveillance, or social control; overcoming property rights, including IP and money, by sharing knowledge, culture, and resources; intelligence, including independent thinking and personal responsibility; and smart machines, specifically the attainment of Friendly Artificial Intelligence that exceeds human ability, through funding and favorable legislation.

Extropians advocate and explore the philosophies of transhumanism (technological enhancement), extropy (improving the human condition), and the future. Numerous prominent cypherpunks also subscribed to the Extropian mailing list, including co-founders of the cypherpunk movement Timothy C. May and Eric Hughes.

Another active member of the extropians was Hal Finney. Finney was co-developer of the first anonymous remailer, the first person to transact Bitcoin with Satoshi and the first maintainer of the Bitcoin codebase. He was cryogenically frozen when he passed away in the hope of living in the future alongside his wife, Fran, who noted that Hal liked the present. But he looked towards the future. For this community, technologies like digital cash offered a way of long-term thinking about the future of humanity, transhumanism, and solutions and preventions for cryogenics, outer space, and catastrophic environmental or societal collapse.

The cypherpunks interest in extropianism, and vice versa, was concerned with building infrastructure today that would sustain the future of human evolution. In some ways, this makes sense.

In order for ones cryogenic suspended animation to be paid for, maintained and reversed to wake them up in the far-flung future where science advances to the point where this aspiration is realized, there needs to be an incentive. In 1994, Wired magazine reported over 27 frozen people (technically 17 frozen heads and 10 entire bodies) at the Alcor Life Extension Foundation, the same company that Roger Ver has signed up with.

Immortality is mathematical, not mystical, stated Mike Perry, their overseer. The hope is that Bitcoin will be a resilient long-term incentive for someone to wake up Hal, Fran and other friends. Herein lies the need for long-term blockchain infrastructure, to last as a secure monetary reward until the century when unfreezing is possible.

Among the principles of extropianism set out by Moore is intelligent technology, meaning technologies that bring beneficial results, including genetic engineering, life-extending bio-sciences, intelligence intensifiers, smarter interfaces to swifter computers, neural-computer integration, worldwide data networks, virtual reality, intelligent agents, swift electronic communications, artificial intelligence, neuroscience, neural networks, artificial life, off-planet migration, and molecular nanotechnology.

Expect to see more life extension, brain-machine interfaces, limb regeneration, curing deafness, bionic sight and more incredible feats in the next decade, states Srinivasan. Transhumanists predict an inevitable singularity, when technology becomes intelligent, uncontrollable and irreversible, to occur around 2035. Blockchain is part of this technology stack.

The lofty, futuristic ideas of transhumanists depend on resilience and digital infrastructure. This is especially true for the goal of friendly artificial intelligence, which is seen as an enabling condition for rapid development across all other core principles of the project. Thanks to blockchain technology, and blockchain philanthropy, we are beginning to have the resources to do it.

An immutable worldwide computer enables a decentralized autonomous organization to allow our uploaded brain image to automatically coordinate with friendly artificial intelligence in a decentralized, freedom-loving way.

Blockchains immutability makes it the perfect long-term infrastructure. Cypherpunks were paranoid about Orwellian dystopias in which authorities would rewrite history to match state propaganda. The architectural and political decentralization of public blockchains means that no one can tamper with, control or delete the record of history. This makes it the perfect record-keeping infrastructure if we are going to live forever.

This is essential when it comes to your brain image or your Bitcoin balance. In order to document who owns what coins when you are cryogenically frozen and woken up in the next century, you need resilient, long-term, tamper-proof blockchains. The values of independence and immutability are essential to both crypto enthusiasts and transhumanists. Buterin states:

Its great that we have people trying to upload or improve brain scanning. Its also great that we have people including cryonics, so we could just go to sleep in the freezer and eventually, hopefully, sometime in the future [] anyone who gets cryogenically frozen will be able to wake up.

The combination of transhumanist philosophy, blockchain technology, community obsession and money enable whole new possibilities. The transhumanist-blockchain vision is that we will all be connected, humans and machine intelligence, through decentralized, automatically executing smart contracts and marketplaces.

Blockchains provide a platform infrastructure to enable a host of technologically advanced human-machine futures. One example is a decentralized marketplace for AI, such as SingularityNET by artificial intelligence researcher, transhumanist, and CEO Ben Goertzel. Here, intelligent computational agents buy, sell and barter over work for digital tokens via a blockchain.

In The Transhumanism Handbook, Melanie Swan predicts that crypto cloudminds, in which mind node peers interact through multicurrency pay channels of digital denominations, will algorithmically enforce good behavior between humans and machines through the privacy and transparency of blockchains. According to Srinivasan, this could also lead to cloud cities, which allow their members to negotiate with other jurisdictions and crowdfund territories in the physical world.

Transhumanism, like human beings, is only in its early stages of development.

Transhumanism, with its focus on superhumans and longevity instead of an afterlife, can be viewed as something akin to a religious impulse. Although many transhumanists take their worldview to be in opposition to religious outlooks on life, transhumanism may become the religion of blockchainers. Yet, this doctrine does not come without a clear burden of responsibility.

While some fear transhumanism, a core tenet is to ensure that technology produces positive outcomes for humanity. Transhumanists advocate that the choice to improve human capacities lies with the individual.

Part of the longevity research agenda is figuring out how to measure the risks of friendly artificial intelligence and make it truly friendly to avoid a catastrophe. Transhumanists want to avoid X risk, which is existential risk to humanity of a hypothetical, global, catastrophic future event that could damage human well-being or destroy human civilization. This is why colonizing outer space is so logical, as Elon and other crypto enthusiasts are pursuing. The Extropian Principles, v. 3.0 by Max Moore from 1998 emphasizes this, stating that migration into space will immensely enlarge the energy and resources accessible to our civilization. Of course, smart machines will also help us explore space because they can handle more gravitational force than humans as they enter the orbit of other planets.

To a transhumanist, the goal of technology is to amplify our abilities and extend human freedoms. How could we ensure humanity lives forever and life spreads throughout the universe? asks Weisser from VitaDAO. Its all about probabilities and increasing the probability that humanity will survive, he says.

A long-term mindset treats aging as an engineering problem. Now, it remains to be seen if the intersection of blockchain philanthropy, VitaDAOs research collective, and other decentralized, transhumanist pursuits will be cautiously and collectively propelled forwards with the kind of long-termism that will benefit humanity. As Buterin states:

I hope you guys can [] come to my thousandth birthday party.

Read the rest here:
Crypto leaders are obsessed with life extension. Here's why Cointelegraph Magazine - Cointelegraph

Recommendation and review posted by Bethany Smith

If 100 is already the new 80, what about living till youre 150 years old? Growing up, my dad, a doctor obsessed with the idea of immortality, would tell how his grandparents back in Lebanon had lived well past the 100-year mark. How? They simply ate well, he used to say, as if their secret was no mystery at all. But back in the mid-19th century, they were the exception to the rule: People generally died much, much earlier.

Today, as humans continue to lust after any number of material and immaterial objects, scientists are researching radical life extension technology like never before. Amazing, right? Lets see. Read on to learn about the great, the weird and the downright costly behind our quest for eternal existence.

Editors note: OZYs all about bringing you the new and the next . . . in fresh ways. Were trying a new look for your favorite newsletter to make your experience even more delicious. Please share your thoughts on the new look below.

Probably. Think about it: 200 years ago, there was no such thing as an active 90-year-old. Fast forward 20 decades, and photos of people breaching the 100-year barrier have become almost routine. Vaccines, antibiotics and a better understanding of what is good for our bodies and minds have taken us far. By 2050, the U.N. estimates there will be 3.7 million centenarians around the world, a major bump from the nearly 600,000 today. How can we push our biological clocks even more, keeping our minds sharp and bodies healthy for longer? One departure is to treat aging as an illness. Thats right. A tribe of scientists, including Steven Austad, a biologist at the University of Alabama, says the key to drastically longer life lies in altering the processes that prevent our very molecules from growing old.

Scientific progress looks promising. Experts have already successfully applied an antifungal used during organ transplants to extend the lives of mice. Just think what that might mean for a human. Thats not all. A string of revolutionary health treatments on the horizon is poised to change how our bodies deal with aging. Heard of a pill that mimics the benefits of exercise? Or drugs that trick our internal clock into thinking its younger? How about nano-robots that find and destroy disease inside our bodies and cell reprogramming? The future of anti-aging medicine is mind-blowing. But dont rush to your doctors office just yet. Despite such theoretical advances, some experts believe our bodies have a built-in expiration date. Not to mention theres a host of issues preventing humans from living longer that must be tackled, starting with poverty, violence, pollution, climate change and traffic accidents.

Can you imagine what you would do if you could live your peak years your 20s and 30s, say over and over? Maybe we use the [extra] years to reimagine the trajectory of life, just like we did 100 years ago, when we invented childhood and retirement, Austad said in a TED Talk. John Davis, a philosophy professor at California State University, Fullerton, brings a similarly philosophical lens to the question. I think people get wiser as they get older, he tells OZY. Given time and life experience, people become more patient, more aware of what a wise choice and a foolish choice looks like, and less violent. So we might find that a society that lives longer is a better society.

Now for the bad news. Increased pressure on already overstretched global health care systems and an inadequate supply of jobs, food and housing are just some of the challenges we face if we were to live for as long as wed like. Longer, healthier lives translate to expanding populations worldwide, a change the planet might not be able to withstand. We are already facing the consequences of overpopulation, Davis says. Its called climate change. The solution there remains controversial and might require something more radical than eternal life.

Outside the lab, futurologists have been putting forth their own takes on life extension. But be warned: you would need deep pockets to access them. Ray Kurzweil, a resident futurist at Google a company currently investing in the study of aging claims that by 2029, medical advances could start adding an additional year, every year, to peoples life expectancy, at least to those who can afford it. Researcher Aubrey de Grey posits that by 2036, many people with access to the right therapies (e.g., working to make our molecules younger) could avoid aging-related diseases or maladies entirely. Is there a catch? Unfortunately, yes. To reach the 150-year-old mark, you might need to live in an environment free of stressors and a wad of cash to cover what will be costly treatments. Tempted by whats being offered by Libella Gene Therapeutics, which claims to reverse aging by up to 20 years? Be prepared to fork over a whopping $1 million.

The price tag may be shocking, and it points to another disturbing truth: Longevity is set to become the new standard-bearer of inequality. And its not strictly a rich-country-versus-poor-country distinction, or even race, which is a major determinant of life expectancy in the U.S. A study by Northwestern University in Illinois found that Americans with a higher net worth at midlife live longer than their poorer counterparts. Even among brothers and sisters, those with greater wealth tend to outlive their siblings. Thats even taking into account identical genetic profiles, meaning the only factor that separates them is money.

Unless, that is, you happen to live in one of the worlds blue zones: a select group of countries in which people have been living longer for reasons unrelated to their bank account. Take Nicoya, for example. Centenarians in this lush Costa Rican peninsula say their secret to a long life is robust social networks and strong family ties. On the other side of the world, Japans super-senior citizens claim that healthy diets and exercise have paved the way to a lengthy and happy existence. Even if Kane Tanaka, the worlds oldest person at 118, admits she loves chocolate and soda. Money, however, can play a role. Just look at Monaco, the uber-wealthy principality where residents live on average to nearly 90 years old.

Dont live in any of those places? Dont despair. Someday there may be another option for those who want to live a lot, lot longer: Upload your consciousness, Black Mirror style. While we are still far from transferring our minds onto a chip, Artificial Intelligence advances could make this sci-fi-sounding proposition a reality. Some people have already signed on to a program to freeze their brains and bodies in liquid nitrogen coffins to preserve the essential parts of their personalities. Cryonics preserves the body until science has progressed to a point where a person could be reanimated and cured of whatever diseases they suffered from. In 2016, a 14-year-old girl with a rare form of cancer won the right to be cryogenically frozen after she died, in the hopes shell be brought back to life once a cure for her disease is discovered.

Yeah, we all know this one. Harvard researchers have found that increasing the amount of red meat you consume may, in some cases, raise the risk of early death. Participants in the experiment who increased their meat consumption by just half a serving per day (around 1.7 ounces) over eight years had a 10% higher risk of dying over the subsequent eight-year period. The studys authors also claim a significant benefit to replacing a portion of your weekly meals with non-meat options. Its not just good for you, its good for the planet. But Jeralean Talley, who lived to 116, might prove the authors wrong. This American super senior told Time in 2013 that one of the secrets to her longevity is a pork-rich diet, especially pigs ears and feet.

Walking an extra 1,000 steps a day could increase your chances of living a long life, according to the American Heart Association. The benefits of incorporating walking into your daily routine were consistent across people who took one long stroll and those who opted for shorter bursts throughout the day. That included going shopping or walking to your car. Heading out for a walk should be a priority for everyone, especially now that remote work is forcing many to park their butts for long stretches. Each increase of 1,000 steps was linked to a 28% decrease in the risk of early death.

When American Loreen Dinwiddie died in 2012 at age 109, she was the worlds oldest vegan. She credited her diet for helping her reach that milestone and for giving her a pep in her step. Its well-known that eating greens keeps you healthy day to day, but it also helps you live longer. Consuming five servings of fruits and veg every day translates to a 13% lower risk of early death. But dont despair, some fun is also allowed. Misao Okawa, the oldest person on the planet before she passed away in 2015 at age 117, said the secret to her long life was simple: eating delicious things including sushi and noodles.

You keep me young isnt just a sweet phrase. A study by researchers at the Boston University School of Medicine in 2014 found that late motherhood can lead to a longer life for women who delivered their last child after 33. In fact, they are twice as likely to live to 95 than those who had their last kid by 29. Furthermore, the New England Centenarian Study, published in 2014, concluded that women who bore children after turning 40 were four times more likely than younger mothers to reach 100 years old. Theres a caveat, though: Just delaying pregnancy wont make you live longer; growing old depends on your genes too. Read more here.

See the original post here:
What Does It Mean to Live Forever? - OZY

Recommendation and review posted by Bethany Smith

Newcrest Mining (ASX:NCM) will pump 246 million big ones into a fifth cutback at Telfers West Dome deposit in a bid to extend the life of the ~30 million ounce WA gold mine.

Newcrest will add two years to the Telfer schedule and prepare for the introduction of the higher grade 3.4Moz Havieron gold-copper project in 2023.

The Paterson province ore body, a 60-40 joint venture between Newcrest and London-listed explorer Greatland Gold, electrified the junior end of the market when it was found back in 2018.

Havieron and Rio Tintos Winu copper mine, which will enter production around 2025, have reinvigorated interest in the gold and copper district wedged between WAs resource rich Goldfields and Pilbara regions.

Newcrest produced 416,138oz of gold and 13,177t of copper at Telfer in the 2021 financial year and saw costs fall to around US$1203/oz in the June quarter at an operating margin of US$577/oz.

Thats decent from a mine once so marginal its threatened closure was central to lobbying by gold miners to avoid a royalty rate hike from the WA Government back in 2017.

This cutback is an investment in Telfers future which will ensure the operation is able to continue for at least the next two years, Newcrest boss Sandeep Biswas said. With additional drilling, we believe there is the potential for further mine life extensions in the open pit and the underground beyond this time.

With the excellent progress we are making at the nearby Havieron project, our objective is to continue utilising the Telfer plant without interruption as we look to introduce Havieron and other new potential feed sources in the future.

There is of course no shortage of juniors drilling away in the Paterson province who could be in line for a Newcrest payday if they find anything of interest.

RBC mining analyst Kaan Peker said the announcement was a sign of confidence in Havieron, which RBC values at $800 million for Newcrests 60 per cent stake.

The capital being spent on the cut-back at Telfer is significant given mine life, but we believe this opens up long-term optionality with Havieron and potential mine-life extension for West Dome, he said in a note. The announcement today flags NCMs confidence in Havieron.

The broader materials sector was dragged down by a massive decline from Rio (ASX:RIO), which lost almost 7% of its value or almost $9.

Iron ore prices rose slightly to halt a major slide in recent days, but Rio went ex-dividend on its record $7.60 a share payout and fell correspondingly.

It has also suffered some damaging PR in the past couple days after a review commissioned by Rio Tintos partners into a delayed expansion of the Oyu Tolgoi mine in Mongolia blamed Rios alleged mismanagement for a US$1.45 billion blow out.

Strong copper prices in the first half of 2021 are likely to give a nice sheen to OZ Minerals half year results, which come out next Wednesday.

$7.7 billion capped OZ is up more than 20% year to date and almost 70% over the past 12 months.

Strong results across the first half of the year, in particular at the Prominent Hill copper-gold mine in South Australia prompted OZ to up guidance for 2021 last month along with the release of its June quarterly.

The miner expects to produce 120,000-145,000t of copper and 205,000-228,000oz of gold at AISC of US$1.30-1.45/lb in 2021.

The major coal stocks on the ASX continue to impress, with Yancoal and Coronado both retracing their early 2021 losses in recent months on the back of higher coking and thermal coal prices.

Chinese-backed Australian coal producer Yancoal is up a tidy 20-odd per cent over the past week, while Coronado has made similar gains despite posting a $96 million loss over the first half of 2021.

Get the latest Stockhead news delivered free to your inbox.

It's free. Unsubscribe whenever you want.

You might be interested in

Follow this link:
Monsters of Rock: Newcrest approves life extension at Telfer as Havieron awaits - Stockhead

Recommendation and review posted by Bethany Smith

Until this week, Aubrey de Grey was best known as the longevity researcher who predicted the first human to live 1,000 years may already be alive. Now, de Grey stands accused of being a sexual predator.

Celine Halioua, who received research funding from de Greys SENS Research Foundation, set out her accusations in a blog post titled Aubrey de Grey is a sexual predator. Laura Deming, founder of life extension VC shop The Longevity Fund, set out separate allegations against de Grey in her own blog post.

Deming wrote: I had one bad experience with him when I was 17he told me in writing that he had an adventurous love life and that it had always felt quite jarring not to let conversations with me stray in that direction given that [he] could treat [me] as an equal on every other level. He sent this from his work email, and Id known him since I was 14.

At the time, Deming said she wrote it off as a mistake. However, in the past few months, in part through conversations with Celine Halioua, Deming has come to believe her experience is part of a serial pattern hes enacted with women over whom hes in a position of power.

The accusations made by Halioua center on a dinner at which she was sat next to de Grey by a SENS executive. I was told to keep him entertained; Aubrey funneled me alcohol and hit on me the entire night. He told me that I was a glorious woman and that as a glorious woman I had a responsibility to have sex with the SENS donors in attendance so they would give money to him, Halioua wrote.

Halioua left that dinner sobbing and said it has taken her years to shake the deep-seated belief that I only got to where I am due to older men wanting to have sex with me. In the post, Halioua accused an unnamed SENS executive of harassing her so severely that she eventually dropped out of my PhD to escape him. Halioua is now CEO of a biotech startup developing drugs to extend dog life span.

De Grey responded to the accusations in a Facebook post. The longevity researcher admitted he inadvisedly wrote the email discussed by Deming and unreservedly regrets having done so. In all other regards, de Grey denies the accusations, which he framed as a setup.

I'm putting it out there right now: if other accusers come forward with supporting evidence, I will step aside a great deal faster than Cuomo just did. But if they don't who's the real culprit here? Hint: in my ever-so-personal view, it's not Celine or Laura. The unequivocally clear conclusion that I draw from the above is that they have been set up, de Grey wrote.

De Grey believes people have deceived Deming and Halioua into the view that I have done many things that I have in fact not done. As to who would orchestrate such a deception and why, de Grey said: I have been vigorously advised to keep my counsel on that question for another day or two but, as they say, watch this space.

SENS has put de Grey on administrative leave. An independent investigation into the allegations, which SENS first learned of in late June, is now underway.

Read more:
Leading longevity researcher accused of sexual harassment - FierceBiotech

Recommendation and review posted by Bethany Smith

WASHINGTON The U.S. Missile Defense Agency is examining the possibility of building a layered ballistic missile defense architecture for the homeland that would bolster the current ground-based system in Alaska, all while a next-generation capability is developed and fielded.

The MDA featured its plan in its fiscal 2021 budget request, but there isnt much of a strategy laid out in its fiscal 2022 funding picture. And so lawmakers want answers before turning on the funding spigot.

Developing such an architecture, even though it would use mostly proven systems, has many hurdles, as MDA Director Vice Adm. Jon Hill said last year.

The plan would include establishing layers of defensive capability relying on the Aegis Weapon System, particularly the SM-3 Block IIA missiles used in the system, and a possible Aegis Ashore system in Hawaii. The underlay would also include the Terminal High Altitude Area Defense system.

The layered approach would buy time while the Pentagon scrambles to field a new interceptor to replace older Ground-Based Interceptors after canceling its effort to redesign the kill vehicle for the GBIs in its Ground-based Midcourse Defense system located at Fort Greely, Alaska, and Vandenberg Space Force Base, California.

The test stressed the system, putting it up against a long-range intercontinental ballistic missile, but the MDA wants to conduct another yet-to-be-scheduled test against a more complex ICBM target with separation debris and countermeasures.

However, the validation of a possible underlay doesnt stop with a few tests. Upgrades will be required based on threats; combat system certifications will need to be conducted; and work must be performed with the Navy to determine where Aegis ships should deploy, Hill said. The agency will also have to determine how quickly it can ramp up its production line for SM-3 Block IIA missiles.

Sign up for our Early Bird Brief Get the defense industry's most comprehensive news and information straight to your inbox

Subscribe

Enter a valid email address (please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D'ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Thanks for signing up!

By giving us your email, you are opting in to the Early Bird Brief.

Hill said last fall that if the agency succeeds with Aegis, it could go down the path with THAAD, then work on engagement coordination between layers.

When the FY22 budget request came out at the end of May, Hill said funding would focus on looking at how the Command and Control, Battle Management, and Communications system could incorporate Aegis and THAAD capabilities for the homeland, and how those systems would be linked to give options to combatant commanders.

But, he added, those decision have not been made to date.

When asked if the agency was cooling on a layered homeland defense, Hill said: I wouldnt say its no longer a priority since we do have investment in the budget, but there are some very serious policy implications, and so we want to make sure that we get the policy angles right.

The agency also wants to make sure its still a need for U.S. Northern Command in light of a now-established service life extension program for the GMDs Ground-Based Interceptors already emplaced, Hill noted. The command did not include layered homeland defense in its list of unfunded requirements sent to Congress in June.

The big concern, back when layered homeland defense was first discussed, was the concern that the existing fleet would start to lose its reliability over time while we also had this timeline for the Next-Generation Interceptor off to the right, Hill said.

Plans for the Next-Generation Interceptor are moving forward with a competition between Lockheed Martin and Northrop Grumman, and theres talk the timeline for first emplacement could be earlier than anticipated.

Yet, Congress is getting impatient over a lack of answers regarding progress toward an architecture that could shore up any gap in capability now and into the future.

During a June 14 hearing with the House Armed Services Committees strategic forces subpanel, Rep. Elise Stefanik, R-N.Y., asked for an update on the report on the layered homeland defense system, which was required in the FY21 National Defense Authorization Act. She noted that the deadline of March 1, 2021, had passed.

Hill responded that, while there are no technical barriers to an underlay, its really a policy question that we need to come through.

Without offering a timeline for delivering a report to Congress, Leonor Tomero, the Pentagons assistant secretary of defense for nuclear and missile defense policy, said at the same hearing: I can assure you that we are looking at what investments we make for a layered homeland defense, what priorities are the subject of studies again in consultation with the Missile Defense Agency and the Office of Cost Assessment and Program Evaluation.

The Defense Department made an initial investment in FY22, Tomero added, and studies will inform further investments in FY23.

The Strategic Forces Subcommittee followed up in its markup of the FY22 authorization bill with a renewed push for a detailed report. The committee would direct the Pentagon to submit a report by the end of 2021 on development and deployment plans for using Aegis with SM-3 Block IIA interceptors as part of a layered missile defense system.

The report should include how Fort Drum, New York, previously identified as an East Coast location for Ground-Based Interceptors, might be used for future layered defense. Stefaniks district includes Fort Drum.

An analysis of how deploying Arleigh Burke-class guided-missile destroyers for homeland defense would affect Navy readiness and global force management would also be required, and the report should contain an applicable manning strategy should land-based Aegis systems be deployed as part of the architecture.

The House Appropriations Committees defense subpanel, in its markup of the FY22 spending bill, took hacks at Defense Department funding applied to the layered homeland defense totaling $203.7 million.

The committee zeroed out Aegis BMD layered homeland missile defense development, cutting all $98.96 million for which the MDA had budgeted, and a total of $64.56 million to work on similar development for THAAD.

According to the MDAs FY22 budget justification documents, the plan for developing Aegis for homeland defense includes refining system-level requirements and development to expand threat and mission space and to increase performance against moderate threats.

The committee noted the funding cut is due to a lack of validated requirements and acquisition strategy.

The Senate Armed Services Committee released a summary of its FY22 authorization bill, but aside from supporting the MDAs pursuit of the NGI, there is nothing else signaling its intentions.

The Senate Appropriations Committees defense subpanel has yet to release its markup of the FY22 spending bill as of press time on Aug. 2.

Software and hardware improvements needed to evolve both THAAD and Aegis systems, will be important to proceed irrespective of whether or not they end up deployed to support a thick defense of the continental United States, Tom Karako, senior fellow with the International Security Program and the direct of the Missile Defense Project at the Center for Strategic and International Studies told Defense News.

The non-recurring engineering planned for the layered defense program elements would be very useful to complete to support regional applications, he added. These systems began as regional defenses, and their continued evolution will benefit regional protection, such as for bases in Guam, Japan, and the like.

See the original post here:
How will the Pentagon close the homeland missile defense gap? - DefenseNews.com

Recommendation and review posted by Bethany Smith

VIDEO ABOVE: Jane Tiller discusses privacy issues surrounding online DNA tests. Watch full ep. here.

Karenne uploaded the data she received from her DNA test to a third party website. Her intention was to find out whether there were any hereditary medical issues in her family.

The very first thing that popped up was two BRCA genes, she told Insight. Which scared me quite considerably.

BRCA is an abbreviation for BReast CAncer gene. BRCA1 and BRCA2 are two different genes that have been found to impact a persons chances of developing breast cancer.

The first course of action for Karenne was to book an appointment with her doctor to talk through her genetic testing discovery. She wanted to get her doctors advice and find out if there was an option for further tests. My doctor pretty much said that it's too hard to be able to test the genes.

But Karenne decided to send her DNA to another direct consumer site for genetic health testing. The results came back with a different cancer gene.

Instead of just affecting breasts, it affects colon, bowel, breast, brain, skin, thyroid, there's a lot more to be concerned about.

After seeing a genetic counsellor Karenne did a colonoscopy at the age of 47. She discovered that she had polyps that may have been on the verge of becoming cancerous.

So by the time I turned 50 I would have already been fighting colon cancer.

Jane Tiller is an ethical, legal and social adviser in public health genomics at Monash University. She said there are few things people need to consider when they do genetic testing through a third party website. Privacy is one of them, she explained, adding that consumers dont know where their data will be sent and who will have access to it.

...People were given risk information that was actually inaccurate.

I think people don't always realise when they check a box to say yes, we'd like this to go to research that it's actually going to a pharmaceutical company for profit rather than maybe to a hospital for cancer research, she told Insight.

We don't always know which companies have those relationships and which don't, certainly in the terms and conditions they should say whether they'll share the data with third parties, whether they'll see your consent for it or not. Most people we know don't read terms and conditions.

Tiller said people also need to make sure the company theyre sending their data to for testing is a reputable company and that they receive accurate information.

A few years ago there was a study where they tried to validate results from interpretation websites and about 40 per cent of results were found to be false positives. People were given risk information that was actually inaccurate.

When you are not going through a clinically accredited genetic test you dont know whether the information you are getting back is accurate or not and whether you should be making decisions based on that.

Karenne is glad she did the test. She is now 50 years old and gets regular colonoscopies. She wants to get to the forefront of any health complication that may emerge. Due to her BRACA genes, (which had mutated increasing the risk of breast cancer) Karenne also underwent a double mastectomy in early 2021.

Im fully recovered now and more relieved and one less thing to worry about.

The rest is here:
How a genetic test led this woman to get a double mastectomy - SBS

Recommendation and review posted by Bethany Smith

FREMONT, Calif., Aug. 12, 2021 /PRNewswire/ -- The premium market intelligence report published by BIS Research on the title Global Direct-to-Consumer Genetic Testing Markethighlights that the market is projected to reach $6.60 billion by 2031. The study also highlights that the market is set to witness a CAGR of 17.30% during the period 2021-2031. The growth of the market is aided by rising government initiatives for the implementation of large sequencing initiatives coupled with the increasing requirement of genetic testing, including the current COVID-19 pandemic.

The global direct-to-consumer (DTC) genetic testing market consists of companies providing genetic testing services without the involvement of healthcare professionals. The DTC genetic testing companies offer genetics testing services for ancestry, health and wellness, and entertainment. Recent trends regarding extensive funding from various investors for the promotion of genetic testing are significantly propelling the market. Also, owing to the emerging concept of consumer empowerment, the global direct-to-consumer genetic testing market is witnessing a massive influx of new entrants in the industry.

Browse 04 Market Data Tables and 104 Figures spread through 187 Pages and in-depth TOC of the Global Direct-to-Consumer Genetic Testing Market Analysis and Forecast, 2021-2031.

The comprehensive study of the global direct-to-consumer genetic testingmarket by BIS Research covers the following:

Who should buy this report?

View the Report from BIS Research: Global Direct-to-Consumer Genetic Testing Market

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include technology, business channel, product type, market share analysis, growth share analysis, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The premium market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, including the higher adoption of genetic tests for early diagnosis of various chronic conditions such as cancer, prenatal screening, and infectious diseases, and increasing awareness among consumers regarding preventive healthcare.

The business channel and product analysis of the global market includes data analysis on the satisfaction level of different kits and services offered by the leading and emerging companies. The study is majorly centered on the sub-segments and micro-segments of the different product markets, such as ancestry, health and wellness, and entertainment.

To emphasize the dominance of the single nucleotide segment over whole genome sequencing under the technology category of direct-to-consumer genetic testing market in 2020 and 2031, Nitish Kumar Singh, Principal Analyst, BIS Research, states, "The reason for market growth can be attributed to the large-scale research and development along with several sequencing initiatives taken globally. The increasing disease burden, including the current COVID-19 pandemic, has led to large capital investments by key players along with the conscious efforts of the manufacturers to ensure data safety and quality of the results obtained after the test."

Request for a Sample: https://bisresearch.com/requestsample?id=1155&type=download

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include 23andme, Inc., Ancestry.com LLC, 24Genetics, Atlas Biomed, Color Genomics, DNAfit, Gene by Gene, 10.9 Chengdu Twenty-Three Rubik's Cube Biotechnology Co., Ltd., Easy DNA, Mapmygenome, Laboratory Corporation of American Holdings, Myriad Genetics, Inc., Konika Minolta, Inc., and XCODE Lifescience, Inc.

The study also offers strategic recommendations that can help organizations track various products, trends, and technologies that are changing the market dynamics. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

How can market intelligence on direct-to-consumer genetic test add value to an organization's decision-making process?

Insightful Questions Covered to Enable Companies take Strategic Decisions

Related Reports:

Global Molecular Diagnostics Point of Care Market - Analysis and Forecast, 2019-2029

Global Molecular Diagnostics Market Analysis and Forecast, 2018-2028

Global Single-Cell-Sequencing Market Analysis and Forecast, 2018-2029

About BIS Research:

BIS Research, a premium market intelligence company, offers in-depth insights and consulting to Fortune 500 companies. We are established and known for tracking the growth of deep technologies across key industry verticals and the subsequent challenges and opportunities associated with deep tech across markets, applications, and products.

With more than 1,000 clients, over 10,000 plus primary interviews, and approximately 200 reports published in a year, BIS Research has often been sighted for its ability to track emerging tech trends early on. We provide market estimations, analysis on emerging high-growth applications, technology analysis, highly segmented granular country-level market data, and other important market parameters that come in handy for our clients during strategic decision-making.

BIS Healthcare provides market-leading insights and data on lab-to-market and early-stage technologies such as precision medicine, robotics and imaging, life sciences and biopharma, and digital health. We have been celebrating the contribution of scientists, academicians, and industry researchers through our highly recognized compendiums Top 25 Voice, such as Healthcare Robotics, Precision Medicine, and Precision Medicine Asia.

Contact: Bhavya Banga Email: [emailprotected] BIS Research Inc. 39111 PASEO PADRE PKWY STE 313,FREMONT CA 94538-1686 Visit our Blog @ https://blog.bisresearch.com/Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research Connect with us on [emailprotected] https://twitter.com/BISResearch

SOURCE BIS Research

Visit link:
Global Direct-to-Consumer Genetic Testing Market to Reach $6.60 Billion by 2031, Says BIS Research Study - PRNewswire

Recommendation and review posted by Bethany Smith

Lyndsay Willmott, MD, discussesthe importance of genetic testing in ovarian cancer.

Lyndsay Willmott, MD, gynecologic oncologist, Arizona Oncology, discussesthe importance of genetic testing in ovarian cancer.

When treating patients withovarian cancer, genetic testing is one of the easiest tools to incorporateinto clinical practice to help guide treatment decisions, according to Willmott. However, becausegenetic counselors are scarcein some areas, it is importantto be an informed advocate for genetic testing so that its use is initiated in the frontline, Willmott says.Additionally,educating patients on the importance of genetic testing can serve to overcome hesitancy and empower them with respect to treatment decisions, Willmott adds.

Moreover, it has been shown that patients with a BRCA mutation may perform better with certain agents, according to Willmott. Although this might not be universal, it is important to counsel patients about the link between mutational status and their available treatment options,Willmott says.Sharing this information with patients will help them to manage expectations regarding their treatment journey and empower them through the clinical decisions that are being made, Willmott concludes.

Follow this link:
Dr. Willmott on the Importance of Genetic Testing in Ovarian Cancer - OncLive

Recommendation and review posted by Bethany Smith

New Jersey, United States,-The latest study on the industrial growth of the DTC Genetic Testing Market 2021-2028. A detailed study has been performed to provide the latest insight into the acute characteristics of the DTC Genetic Testing market. The report provides various market forecasts related to market size, revenue, production, CAGR, consumption, gross margin, price, and other critical factors. The report not only emphasizes the major driving and restraining forces in this market but also offers a comprehensive study of future trends and developments in the market. It also studies the roles of leading players in the industry market including their company overview, financial summary, and SWOT analysis.

This report analyzes the impact of the COVID-19 pandemic on market growth and sales. The report also includes an in-depth analysis of the current and future impact of the pandemic and post-COVID-19 scenario analysis.

Get | Download Sample Copy @ https://www.marketresearchintellect.com/download-sample/?rid=435683

The report provides a detailed analysis of the major market players along with an overview of their business, expansion plans, and strategies. The main actors examined in the report include:

DTC Genetic Testing Market: Key Catalysts

The market is further subdivided according to end-user type and application. The report also includes an assessment of the segment that is expected to be the market leader over the forecast years. The report provides detailed market segmentation by type and application along with historical data and forecast.

The report further studies the market segmentation based on the types of products offered in the market and their end-uses/uses.

While segmenting the Market by DTC Genetic Testing Types, the Report includes:

While segmenting the Market by DTC Genetic Testing Applications, the report covers the following application areas:

Ask for a Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=435683

DTC Genetic Testing Market Report Scope

Due to the regional segmentation, the market is divided into the main regions North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. In addition, the regional analysis covers the breakdown of the market and key players by country.

The research report offered by the Market Research Intellect provides an updated view of the global DTC Genetic Testing market. The report provides a detailed analysis of the key trends and emerging market factors that could affect the growth of the industry. Additionally, the report studies market features, competitive landscape, market size and growth, regional split, and strategies for this market.

DTC Genetic Testing Report Content Highlights:

DTC Genetic Testing World Market Review

Market competition from players and manufacturers

competitive environment

Production, estimate of sales by type and application

Regional analysis

Analysis of the industrial chain

Forecast of the world market DTC Genetic Testing

For more informative information, please visit us @ https://www.marketresearchintellect.com/product/global-dtc-genetic-testing-market-size-and-forecast/

Visualize DTC Genetic Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment and Key players of your market. Present your Market Report & findings with inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize DTC Genetic Testing Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

Thank you for reading our report. The report can be customized based on chapters or regions. Contact us to learn more about customization options and our team will make sure you generate a report based on your needs.

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering customized and in-depth research studies.

Our advanced analytical research solutions, custom consulting and in-depth data analysis cover a range of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages. Etc

Our research studies help our clients to make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information without compromise.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.Contact us:

Mr. Edwyne Fernandes

Market Research IntellectUS: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Website https://www.marketresearchintellect.com/

Read the original here:
DTC Genetic Testing Market Size, Analytical Overview, Growth and Forecast to 2028 - The Market Writeuo - The Market Writeuo

Recommendation and review posted by Bethany Smith

The Latest Released Preimplantation Genetic Testing Market study has evaluated the future growth potential of Global Preimplantation Genetic Testing market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Preimplantation Genetic Testing market. The study includes market share analysis and profiles of players such as Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

If you are a Preimplantation Genetic Testing manufacturer and would like to check or understand policy and regulatory proposal, designing clear explanations of the stakes, potential winners and losers, and options for improvement then this article will help you understand the pattern with Impacting Trends.

Major Highlights of the Preimplantation Genetic Testing Market report released by Adroit Market Research

Market Breakdown by Applications: .

Market Breakdown by Types: by Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) and Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism)

Revenue and Sales Estimation Historical Revenue and sales volume is presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well recognized Types and end-use industry.

SWOT Analysis on Preimplantation Genetic Testing Players

In additional Market Share analysis of players, in-depth profiling, product/service and business overview, the study also concentrates on BCG matrix, heat map analysis, FPNV positioning along with SWOT analysis to better correlate market competitiveness.

Demand from top notch companies and government agencies are expected to rise as they seek more information on latest scenario. Check Demand Determinants section for more information.

Regulation Analysis

Local System and Other Regulation: Regional variations in Laws for the use of Preimplantation Genetic Testing

Regulation and its Implications

Other Compliances

FIVE FORCES & PESTLE ANALYSIS:

In order to better understand Preimplantation Genetic Testing Market condition five forces analysis is conducted that includes Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, Threat of rivalry.

Political (Political policy and stability as well as trade, fiscal and taxation policies)

Economical (Interest rates, employment or unemployment rates, raw material costs and foreign exchange rates)

Social (Changing family demographics, education levels, cultural trends, attitude changes and changes in lifestyles)

Technological (Changes in digital or mobile technology, automation, research and development)

Legal (Employment legislation, consumer law, health and safety, international as well as trade regulation and restrictions)

Environmental (Climate, recycling procedures, carbon footprint, waste disposal and sustainability)

Heat map Analysis, 3-Year Financial and Detailed Company Profiles of Key & Emerging Players:Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

Geographically, the following regions together with the listed national/local markets are fully investigated:

APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

North America (U.S., Canada, and Mexico)

South America (Brazil, Chile, Argentina, Rest of South America)

MEA (Saudi Arabia, UAE, South Africa)

Global Preimplantation Genetic Testing Market Size (Sales) Market Share by Type (Product Category) [, Lifetime Preimplantation Genetic Testing, Regular Preimplantation Genetic Testing, Union Preimplantation Genetic Testing & Variable Preimplantation Genetic Testing] in 2020

Preimplantation Genetic Testing Market by Application/End Users []

Global Preimplantation Genetic Testing Sales and Growth Rate (2015-2028)

Preimplantation Genetic Testing Competition by Players/Suppliers, Region, Type and Application

Preimplantation Genetic Testing (Volume, Value and Sales Price) table defined for each geographic region defined.

Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis

..and view more in complete table of Contents

About Us

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

More:
Dissecting Growth Strategies for Preimplantation Genetic Testing Market by Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer -...

Recommendation and review posted by Bethany Smith